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A B S T R A C T
Background
Human breast milk-fed preterm infants can accumulate nutrient deficits leading to extrauterine growth restriction. Feeding preterm infants
with multi-nutrient fortified human milk could increase nutrient accretion and growth rates and improve neurodevelopmental outcomes.
Concern exists, however, that multi-nutrient fortifiers are associated with adverse events such as feed intolerance and necrotising
enterocolitis.
Objectives
To determine whether multi-nutrient fortified human milk, compared with unfortified human milk, aHects important outcomes (including
growth rate and neurodevelopment) of preterm infants without increasing the risk of adverse eHects (such as feed intolerance and
necrotising enterocolitis).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 9), MEDLINE via PubMed (1966 to 26 September 2019),
Embase (1980 to 26 September 2019), and the Cumulative Index to Nursing and Allied Health Literature (CINAHL; 1982 to 26 September
2019). We searched clinical trials databases, conference proceedings, and reference lists of retrieved articles for randomised controlled
trials and quasi-randomised trials.
Selection criteria
Randomised and quasi-randomised controlled trials that compared feeding preterm infants with multi-nutrient (protein and energy plus
minerals, vitamins, or other nutrients) fortified human breast milk versus unfortified (no added protein or energy) breast milk.
Data collection and analysis
We used the standard methods of Cochrane Neonatal. Two review authors separately evaluated trial quality, extracted data, and
synthesised eHect estimates using risk ratios (RRs), risk diHerences, and mean diHerences (MDs). We assessed the certainty of the body of
evidence at the outcome level using "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) methods.
Main results
We identified 18 trials in which a total of 1456 preterm infants participated. These trials were generally small and methodologically weak.
Meta-analyses provided low- to moderate-certainty evidence showing that multi-nutrient fortification of human milk increases in-hospital
rate of weight gain (MD 1.76 g/kg/d, 95% confidence interval (CI) 1.30 to 2.22), body length (MD 0.11 cm/week, 95% CI 0.08 to 0.15), or
head circumference (MD 0.06 cm/week, 95% CI 0.03 to 0.08) among preterm infants. Few data on growth and developmental outcomes
assessed beyond infancy are available, and these do not show eHects of multi-nutrient fortification. The data do not suggest other benefits
Multi-nutrient fortification of human milk for preterm infants (Review)
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or harms and provide low-certainty evidence suggesting eHects of multi-nutrient fortification on the risk of necrotising enterocolitis in
preterm infants (typical RR 1.37, 95% CI 0.72 to 2.63; 13 studies, 1110 infants).
Authors' conclusions
Feeding preterm infants with multi-nutrient fortified human breast milk compared with unfortified human breast milk is associated with
modest increases in in-hospital growth rates. Evidence is insuHicient to show whether multi-nutrient fortification has any eHect on long-
term growth or neurodevelopment.
P L A I N   L A N G U A G E   S U M M A R Y
Multi-nutrient fortification of breast milk for preterm infants
Review question: Do preterm infants (babies born early) grow and develop better when they are fed breast milk supplemented with extra
protein and calories ("fortified")?
Background: Breast milk alone might not be enough to support preterm infants to grow and develop optimally. Extra nutrients, such as
protein and energy (calories) from carbohydrates or fat, can be added to breast milk to make it about 10% to 20% more nutritious. These
additional nutrients are called "fortifiers". Feeding preterm infants, especially very preterm infants (born before 32 weeks), fortified breast
milk may mean that they take in more nutrients, grow faster, and develop better.
Study characteristics: We included 18 trials; most were small (involving 1456 infants in total) and had some design weaknesses that might
bias their findings. The search is up-to-date as of September 2019.
Key results: Preterm infants who were fed fortified breast milk put on weight and grew in length and head size a little more quickly while
they were in-hospital. The trials we included did not report a lot of information about the eHects fortified breast milk might have on
development and growth later in the baby's life. The data we have available do not suggest an eHect of feeding fortified breast milk on
outcomes when the child is older. The included trials provide no consistent evidence of other potential benefits or harms of fortified breast
milk, including any eHects on feeding or bowel problems.
Conclusion: Trial data show that multi-nutrient fortification increases growth rates of preterm infants during their first hospital admission
but do not provide enough evidence to show any eHects on longer-term growth or development. New trials are needed to discover more
about this issue.
Certainty of evidence: We assessed this evidence for eHects on growth as being of "low or moderate certainty" because the included
trials were small, had methodological weaknesses, and reported findings that were inconsistent with each other. This means that further
research is very likely to have an important impact on the estimates of eHect and on our confidence in study findings.
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Summary of findings 1.   Multi-nutrient fortification of human milk for preterm infants
Patient or population: preterm infants
Setting: healthcare setting
Intervention: fortified breast milk
Comparison: unfortified breast milk
Anticipated absolute effects* (95% CI)Outcomes
Risk with unforti-
fied breast milk
Risk with fortified breast milk
Relative ef-
fect
(95% CI)
Number of par-
ticipants
(studies)
Quality of the
evidence
(GRADE)
Weight gain (g/kg/d) Comparator Mean weight gain was 1.76 g/kg/d more (1.30 more to 2.22
more)
- 951
(14 RCTs)

Lowa,b
Length gain (cm/week) Comparator Mean length gain was 0.12 cm/week more (0.07 more to
0.17 more)
- 741
(10 RCTs)

Lowa,b
Head growth (cm/week) Comparator Mean head growth was 0.08 cm/week more (0.04 more to
0.12 more)
- 821
(11 RCTs)

Moderateb
Mental development index
(MDI) at 18 months
Comparator Mean MDI was 2.2 more (3.35 fewer to 7.75 more) - 245
(1 RCT)

Moderatec
Psychomotor development in-
dex (PDI) at 18 months
Comparator Mean PDI was 2.4 more (1.9 fewer to 6.7 more) - 245
(1 RCT)

Moderatec
Study populationNecrotising enterocolitis
26 per 1000 40 per 1000
(19 to 68)
RR 1.37
(0.72 to
2.63)
1110
(13 RCTs)

Lowb,c
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
aDowngraded one level for inconsistency in eHect estimates (moderate or high heterogeneity; I2 > 50%).
bDowngraded one level for serious study limitations due to high risk of bias (uncertainty about methods used to generate random sequence, conceal allocation, and blind
assessments) in most trials.
cDowngraded one level for imprecision of eHect estimate (95% CI around estimate consistent with substantial harm or benefit).
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B A C K G R O U N D
Description of the condition
Most preterm infants accumulate nutrient deficits during the
initial neonatal unit admission (Embleton 2001; Cooke 2004). By
the time they are ready to go home, typically at around 36
to 40 weeks' postmenstrual age, many infants, especially those
born very preterm or very low birth weight (VLBW), are growth-
restricted relative to their term-born peers (Ehrenkranz 1999;
Steward 2002; Clark 2003; Dusick 2003). Although very preterm
or VLBW infants usually attain some "catch-up" growth following
hospital discharge, growth deficits can persist through childhood
and adolescence and into adulthood (Dusick 2003; Euser 2008).
Slow postnatal growth is associated with neurodevelopmental
impairment and poorer cognitive and educational outcomes
(Brandt 2003; Leppanen 2014). Preterm infants who have
accumulated mineral deficits have higher risks of metabolic bone
disease and slow skeletal growth compared with infants born at
term, although uncertainty remains about long-term eHects on
bone mass and health (Fewtrell 2011). Furthermore, concern exists
that growth restriction in utero and during infancy may have
consequences for long-term metabolic and cardiovascular health
(Embleton 2013; Lapillonne 2013).
Description of the intervention
Multi-nutrient fortification of breast milk
Human breast milk is the recommended enteral nutrition for infants
(Section on Breastfeeding 2012). Breast milk alone, however, might
not meet the recommended nutritional needs of growing preterm
infants (Embleton 2007; Agostoni 2010). International consensus
guidelines state that "standard" volumes of breast milk (about
150 to 180 mL/kg/d) do not provide the recommended amount
of energy (110 to 135 kcal/kg/d) or protein (3.5 to 4.5 g/kg/d) to
meet the metabolic needs of preterm infants (AAP 2004; Agostoni
2010). The strategy most commonly employed in neonatal care
facilities in high-income countries to address these deficits is to
supplement human breast milk with extra nutrients, usually in the
form of a powder or liquid "multi-nutrient fortifier" (Gregory 2012;
Klingenberg 2012; Cormack 2013; Tudehope 2013; Dutta 2015).
Most commercially available multi-nutrient fortifiers are derived
from cow's milk, but fortifiers derived from human milk have been
developed (Rochow 2015).
Fortifiers are intended to be mixed with expressed breast milk
with the aim of achieving about 10% to 20% nutrient enrichment
while maintaining optimal protein-to-energy ratios to promote lean
mass growth (Embleton 2007; Agostoni 2010; Moya 2012; Section
on Breastfeeding 2012; Tudehope 2013). Multi-nutrient fortification
may be especially important for infants who receive donated
(donor) human breast milk, which typically contains lower levels of
protein, energy, and minerals than their own mother's expressed
breast milk (Arslanoglu 2013). Commercially available fortifiers
are expensive, and their use is limited in resource-poor settings
in low- or middle-income countries (Chawla 2008; Kler 2015). An
alternative strategy employed in resource-limited settings is to add
cow's milk formula powder to human breast milk to nutrient-enrich
by the required amount (Gross 1993).
Targeted and adjustable fortification
Nutrient (especially energy and protein) content of expressed
breast milk varies between mothers and between diHerent batches
of a woman's expressed breast milk (de Halleux 2013). If the
nutrient levels in expressed breast milk are measured, the amount
of fortifier added can be targeted (also referred to as individualised)
to achieve a desired content (Rochow 2013; Rochow 2015). The
level of fortification may be adjusted in response to the metabolic
demands and responses of individual infants, for example, by
titration to the infant's blood urea nitrogen level (Arslanoglu 2010).
How the intervention might work
Multi-nutrient fortification, that is, feeding preterm infants with
human breast milk fortified with protein and non-protein energy
(carbohydrate or fat), as well as minerals and other nutrients, may
be expected to promote nutrient accretion and growth (increase
in weight, length, and head circumference). High levels of nutrient
intake during this critical period might be especially important for
infants who are not able to consume large quantities of milk, who
have slow growth, or who have ongoing additional nutritional and
metabolic requirements (Agostoni 2010).
A potential disadvantage of multi-nutrient fortification is that
increasing nutrient density and osmolarity of human breast milk
might interfere with gastric emptying and intestinal peristalsis,
resulting in feed intolerance or increasing the risk of necrotising
enterocolitis (Ewer 1996; McClure 1996; Gathwala 2008; Yigit 2008;
Morgan 2011). Several cases of subacute bowel obstruction due to
impaction with "milk curd" have been reported in very preterm
infants fed multi-nutrient fortified human breast milk, putatively
due to the high calcium content causing fat malabsorption
(Flikweert 2003; Wagener 2009; Stanger 2014).
Furthermore, investigators have been concerned that accelerated
weight gain during this critical early phase might be associated
with altered fat distribution and related "programmed" metabolic
consequences that may increase long-term risks of insulin
resistance and hypertension (Euser 2005; Singhal 2007; Euser 2008).
Why it is important to do this review
Given the potential for multi-nutrient fortification of human breast
milk to aHect important outcomes for preterm infants, this review
aims to detect, appraise, and synthesise available evidence from
randomised controlled trials to inform practice and research.
O B J E C T I V E S
To determine whether multi-nutrient fortified human milk,
compared with unfortified human milk, aHects important
outcomes (including growth rate and neurodevelopment) of
preterm infants without increasing the risk of adverse eHects (such
as feed intolerance and necrotising enterocolitis).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled trials, including
cluster-randomised controlled trials. We did not include cross-over
trials.
Multi-nutrient fortification of human milk for preterm infants (Review)
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Types of participants
Preterm (< 37 weeks' gestational age) and low birth weight (< 2500
g) infants receiving human breast milk.
Types of interventions
Multi-nutrient fortification of human breast milk (expressed
maternal or donor or both) with protein and  non-protein
energy (carbohydrate or fat). Multi-nutrient fortifiers additionally
could contain minerals, iron, vitamins, or other nutrients. Multi-
nutrient fortifiers could be cow (or another animal) milk-based
or human milk-based. The control group should not have
received protein or non-protein energy fortification but could have
received milk supplemented with minerals, iron, vitamins, or other
nutrients.
Eligible trials should have planned to allocate the trial intervention
for a suHicient period (at least two weeks) to allow measurable
eHects on growth. Infants in comparison groups within each
trial should have received similar care other than the level of
fortification of breast milk. No between-group diHerences in target
levels of volume of milk intake should have occurred.
We did not include trials of:
• targeted or adjustable fortification (vs standard fortification);
• early versus later introduction of multi-nutrient fortifier; or
• human milk-based versus cow milk-based fortifier
Types of outcome measures
Primary outcomes
• Growth: weight, length, head growth, skinfold thickness, body
mass index, and measures of body composition (lean/fat mass)
and growth restriction (proportion of infants who remain <
10th percentile for the index population distribution of weight,
length, or head circumference)
• Neurodevelopmental outcomes assessed aTer 12 months
post term: neurological evaluations, developmental scores,
and classifications of disability, including auditory and visual
disability. We defined neurodevelopmental impairment as the
presence of one or more of the following: non-ambulant
cerebral palsy, developmental quotient more than two standard
deviations below the population mean, and blindness (visual
acuity < 6/60) or deafness (any hearing impairment requiring or
unimproved by amplification)
Secondary outcomes
• Duration of hospital admission (weeks)
• Feed intolerance that results in cessation of or reduction in
enteral feeding
• Necrotising enterocolitis (modified Bell stage 2/3; Walsh 1986)
• Measures of bone mineralisation such as serum alkaline
phosphatase level, or bone mineral content assessed by dual
energy X-ray absorptiometry (DEXA) and clinical or radiological
evidence of rickets on long-term follow-up (restricted to trials
without mineral supplementation of the control group)
• Measures of long-term metabolic or cardiovascular health,
including insulin resistance, obesity, diabetes, and hypertension
Search methods for identification of studies
We used the standard search strategy of Cochrane Neonatal.
Electronic searches
We updated the searches to identify reports of trials available since
the searches in December 2014 and February 2016 (Appendix 1).
We searched these databases on 26 September 2019: the Cochrane
Central Register of Controlled Trials, in the Cochrane Library (2018,
Issue 9), MEDLINE ALL (Ovid), Embase (Ovid), the Cumulative Index
to Nursing and Allied Health (CINAHL) Complete (EBSCO), and
Maternity and Infant Care (Ovid). We imported and de-duplicated
search results against previous search results from December 2014.
We did not apply any language restrictions.
We searched clinical trials registries for ongoing or recently
completed trials on 30 September 2019 (ClinicalTrials.gov and the
World Health Organization’s International Trials Registry Platform -
https://www.who.int/ictrp/en/).
Searching other resources
We examined the references in studies identified as potentially
relevant. We also searched abstracts from annual meetings of
the Pediatric Academic Societies (1993 to 2019), the European
Society for Paediatric Research (1995 to 2019), the UK Royal
College of Paediatrics and Child Health (2000 to 2019), and the
Perinatal Society of Australia and New Zealand (2000 to 2019).
We considered trials reported only as abstracts to be eligible
if suHicient information was available from the report, or from
contact with study authors, to fulfil the inclusion criteria.
Data collection and analysis
We used the standard methods of Cochrane Neonatal.
Selection of studies
One review author (JVEB) screened titles and abstracts of all
records identified by the search and coded records as "order" or
"exclude". A second review author (LL) assessed all records coded
as "order" and made the final decision about which records were
ordered as full-text articles. JVEB read the full texts and used a
checklist to assess each article's eligibility for inclusion on the basis
of pre-specified inclusion and exclusion criteria. WM checked these
decisions.
Data extraction and management
Two review authors (JVEB and LL) extracted data independently
using a data collection form to aid extraction of information
on design, methods, participants, interventions, outcomes, and
treatment eHects from each included study. We discussed
disagreements until we reached consensus. If data from the
trial reports were insuHicient, we contacted trialists for further
information.
Assessment of risk of bias in included studies
Two review authors (JVEB and LL) independently assessed the
risk of bias (low, high, or unclear) of all included trials using
the Cochrane ‘Risk of bias’ tool (Higgins 2019) for the following
domains.
• Sequence generation (selection bias).
Multi-nutrient fortification of human milk for preterm infants (Review)
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• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
Any disagreements were resolved by discussion or by a third
assessor (WM).
See Appendix 2 for a description of risk of bias for each domain.
Measures of treatment e8ect
We analysed treatment eHects in the individual trials using Review
Manager 5.3 and reported risk ratios (RRs) and risk diHerences
(RDs) for dichotomous data, and mean diHerences (MDs) for
continuous data, with respective 95% confidence intervals (CIs). We
determined the number needed to treat for an additional beneficial
outcome (NNTB) or an additional harmful outcome (NNTH) for
analyses with a statistically significant diHerence in the RD.
Unit of analysis issues
The unit of analysis was the participating infant in individually
randomised trials. For cluster-randomised trials (had we identified
any for inclusion), we planned to undertake analyses at the level
of the individual while accounting for clustering in the data using
methods recommended in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2019).
Dealing with missing data
We requested additional data from trial investigators when data
on important outcomes were missing or were reported unclearly.
When data were still missing, we examined the impact of this on
eHect size estimates in sensitivity analyses.
Assessment of heterogeneity
We examined treatment eHects in individual trials and
heterogeneity between trial results by inspecting the forest plots
if more than one trial was included in a meta-analysis. We
calculated the I2 statistic for each analysis to quantify inconsistency
across studies and to describe the percentage of variability in
eHect estimates that may be due to heterogeneity rather than to
sampling error. If we detected moderate (I2 > 50%) or high (I2 >
75%) heterogeneity, we explored possible causes (e.g. diHerences
in study design, participants, interventions, or completeness of
outcome assessments).
Assessment of reporting biases
For outcomes with 10 or more trials contributing events in
the meta-analysis, we investigated reporting biases (such as
publication bias) using funnel plots. We assessed funnel plot
asymmetry visually. If asymmetry was suggested by a visual
assessment, we performed exploratory analyses to investigate this,
including exploration of diHerences in study design, participants,
interventions, or completeness of outcome assessments.
Data synthesis
We used fixed-eHect models for meta-analysis (as per
Cochrane Neonatal recommendations). When moderate or high
heterogeneity existed, we planned to examine the potential causes
in subgroup and sensitivity analyses.
Subgroup analysis and investigation of heterogeneity
We planned to undertake these subgroup analyses, when possible.
• Very preterm (< 32 weeks' gestation) or VLBW (< 1500 g) infants
(versus infants 32 to 36 weeks' gestation or birth weight 1500 to
2499 g).
• Fortification of donor breast milk (versus maternal expressed
breast milk).
• Trials using fortifier extracted from human milk (versus cow
milk-based fortifier).
• Trials supplementing breast milk with infant formula (versus
cow milk-based fortifier).
• Trials conducted in low- and middle-income countries versus
those in high-income countries (see http://data.worldbank.org/
about/country-classifications).
Sensitivity analysis
If meta-analyses were moderately or highly heterogeneous
(I2 > 50%), we planned sensitivity analyses to determine
whether findings were aHected (and heterogeneity reduced) by
including only studies at low overall risk of bias, defined as
adequate randomisation and allocation concealment, masking of
intervention and measurement, and < 10% loss to follow-up for
outcome assessment.
Summary of findings and assessment of the certainty of
evidence
We used the "Grading of Recommendations Assessment,
Development and Evaluation" (GRADE) approach, as outlined in
the Grade Handbook (Schünemann 2013), to assess the certainty
of evidence for these outcomes: growth, development, and
necrotising enterocolitis.
Two review authors (WM and JVEB) independently assessed the
certainty of evidence for each of the outcomes. We considered
evidence from randomised controlled trials as high certainty but
downgraded the evidence one level for serious (or two levels for
very serious) limitations based upon the following: design (risk of
bias), consistency across studies, directness of evidence, precision
of estimates, and presence of publication bias (see Appendix 3).
We used the GRADEpro GDT Guideline Development Tool to create
a ‘Summary of findings’ table to report the certainty of evidence
(GRADEpro GDT).
Summary of findings and assessment of the certainty of the
evidence
We used the "Grading of Recommendations Assessment,
Development and Evaluation" (GRADE) approach, as outlined in
the Grade Handbook (Schünemann 2013), to assess the certainty
of evidence of these outcomes: growth, development, necrotising
enterocolitis.
Two review authors (WM and JVEB) independently assessed the
certainty of the evidence for each of the outcomes. We considered
evidence from randomised controlled trials as high certainty but
downgraded the evidence one level for serious (or two levels for
very serious) limitations based upon the following: design (risk
of bias), consistency across studies, directness of the evidence,
precision of estimates, and presence of publication bias (see
Appendix 3). We used the GRADEpro GDT Guideline Development
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Tool to create nine ‘Summary of findings’ tables to report the
certainty of the evidence (GRADEpro GDT).
R E S U L T S
Description of studies
See Characteristics of included studies and Characteristics of
excluded studies.
Results of the search
ATer searching all of the databases and trial registers, we had
retrieved 3620 records. We de-duplicated these against results from
previous searches carried out for this review. This leT 1170 unique
records. We identified one additional record from a diHerent source
and screened 1171 titles and abstracts, of which we excluded 1159
as irrelevant.
We assessed 11 studies as full text; we included four of these and
excluded the remaining seven.
See Figure 1 for the study selection process and Characteristics of
included studies and Characteristics of excluded studies for further
detail on the studies we considered for inclusion in this review.
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Figure 1.   Study flow diagram.
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Included studies
We included in this review 18 trials (17 primary publications)
in which 1456 infants participated (Modanlou 1986; Gross 1987
(1); Gross 1987 (2); Pettifor 1989; Polberger 1989; Porcelli 1992;
Zuckerman 1994; Lucas 1996; Wauben 1998; Nicholl 1999; Faerk
2000; Bhat 2003; Mukhopadhyay 2007; Gathwala 2012; EinloT 2015;
El Sakka 2016; Gupta 2018; Adhisivam 2019). Sample sizes ranged
between 14 and 275 participants.
All trials were conducted in specialist paediatric hospitals, typically
in neonatal intensive care units. Fourteen were single-centre
trials (Modanlou 1986; Gross 1987 (1); Gross 1987 (2); Pettifor
1989; Porcelli 1992; Zuckerman 1994; Nicholl 1999; Bhat 2003;
Mukhopadhyay 2007; Gathwala 2012; EinloT 2015; El Sakka 2016;
Gupta 2018; Adhisivam 2019), and each of the remaining four was
conducted at two centres (Polberger 1989; Lucas 1996; Wauben
1998; Faerk 2000).
The trials were conducted in Europe (Polberger 1989; Porcelli
1992; Lucas 1996; Nicholl 1999; Faerk 2000), Asia (Bhat 2003;
Mukhopadhyay 2007; Gathwala 2012; Gupta 2018; Adhisivam 2019),
North America (Modanlou 1986; Gross 1987 (1); Gross 1987 (2);
Wauben 1998), Africa (Pettifor 1989; Zuckerman 1994; El Sakka
2016), and South America (El Sakka 2016). Publication dates span
four decades, ranging from 1986 to 2019.
Participants
All trials included preterm or LBW infants and excluded those
with major congenital abnormalities. Eleven trials restricted
participation to very preterm or VLBW infants (Modanlou 1986;
Pettifor 1989; Polberger 1989; Zuckerman 1994; Nicholl 1999; Faerk
2000; Bhat 2003; Mukhopadhyay 2007; EinloT 2015; El Sakka 2016;
Gupta 2018). Adhisivam 2019 enrolled "healthy preterm infants"
without specifying a birth weight criterion. Other trials specified the
upper birth weight eligibility threshold as:
• 1600 g (Gross 1987 (1); Gross 1987 (2));
• 1800 g (Gathwala 2012; Wauben 1998);
• 1850 g (Lucas 1996); or
• 2000 g (Porcelli 1992).
Interventions
Six trials used only maternal breast milk (Pettifor 1989; Zuckerman
1994; Wauben 1998; EinloT 2015; El Sakka 2016; Gupta 2018) One
trial used only donor human breast milk (Adhisivam 2019). Seven
trials used a mixture of mother's own milk and donor milk (Gross
1987 (1); Gross 1987 (2); Polberger 1989; Porcelli 1992; Nicholl 1999;
Faerk 2000; Mukhopadhyay 2007). Investigators in the remaining
four trials used formula to supplement maternal milk feeds to the
required volume (Modanlou 1986; Lucas 1996; Bhat 2003; Gathwala
2012).
Types of multi-nutrient fortification added to milk for infants in
the intervention groups varied. Most trials used a commercially
available, cow's milk-based, powdered preparation containing
varying amounts of protein, fat, carbohydrate, minerals,
electrolytes, and trace minerals.
• Similac Human Milk Fortifier (Ross Laboratories): Gross 1987 (1);
Gross 1987 (2). Gross 1987 (1) included a third group of infants
receiving human milk fortified with formula (see below).
• FM85 (Nestlè): Porcelli 1992; EinloT 2015.
• Enfamil HMF (Mead Johnson): Lucas 1996.
• Nutriprem (Cow & Gate Nutricia): Nicholl 1999.
• Eoprotin (Milupa): Faerk 2000.
• Lactodex HMF (Raptakos Brett): Mukhopadhyay 2007; Gathwala
2012; Adhisivam 2019.
• Trial-specific multi-nutrient fortifier (Wyeth-Ayerst): Wauben
1998.
Four trials used preterm formula powder as the multi-nutrient
fortifier.
• Similac Special Care (Ross Laboratories): Gross 1987 (1).
• Alprem (Nestlè): Zuckerman 1994.
• Bebelac Premature (Nutricia): El Sakka 2016.
• Simyl LBW (FDC Ltd): Gupta 2018.
Three trials did not specify the name or manufacturer of the multi-
nutrient fortifier used: Modanlou 1986; Polberger 1989; Bhat 2003.
Participants received the intervention when tolerating a specified
quantity of milk feeds daily, typically at least 100 mL/kg, or when
receiving "full" enteral feeds, typically 150 mL/kg/d. The duration of
intervention varied between trials, but the intervention was usually
provided until a pre-specified body weight was attained (most
commonly, 1800 to 2000 g), or until a pre-specified postmenstual
age (36 weeks), or until discharge home from hospital.
Comparators
Most trials added vitamins, minerals, or other nutrients to control
infant feeds as part of standard hospital practice. Five trials
provided all infants with additional vitamin D (Pettifor 1989; Porcelli
1992; Zuckerman 1994; Faerk 2000; El Sakka 2016). Eight trials
provided all infants with multi-vitamins, iron, and minerals (added
to feeds for infants in the control group, and included in the fortifier
or added separately for infants in the intervention group) (Gross
1987 (1); Gross 1987 (2); Polberger 1989; Lucas 1996; Wauben 1998;
EinloT 2015; Gupta 2018; Adhisivam 2019). Researchers in five trials
gave no supplements at all to control group infants (Modanlou
1986; Nicholl 1999; Bhat 2003; Mukhopadhyay 2007; Gathwala
2012).
Outcomes
Fourteen trials reported in-hospital growth rate data (Modanlou
1986; Gross 1987 (1); Gross 1987 (2); Pettifor 1989; Polberger
1989; Porcelli 1992; Lucas 1996; Wauben 1998; Nicholl 1999;
Mukhopadhyay 2007; EinloT 2015; El Sakka 2016; Gupta
2018; Adhisivam 2019). Only Lucas 1996 reported growth and
neurodevelopmental data at follow-up beyond hospital discharge.
Excluded studies
See Characteristics of excluded studies for details. We excluded:
• Carey 1987; Greer 1988; and Atchley 2019 because they used
fortification with protein only (no fortification with fat or
carbohydrate);
• Arco 2002; Tarcan 2004; Arslanoglu 2009; Reali 2010; Hair 2014;
and Ramaswamy 2019 because they were not randomised
controlled trials;
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• Abrams 2014 because it compared human versus cow's milk-
based protein fortification rather than fortification versus no
fortification; and
• Chan 2000; Miura 2009; and Kim 2015 because these trials
conducted comparisons of diHerent fortifiers, with no control
group receiving unfortified milk.
Risk of bias in included studies
See Figure 2.
 
Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Adhisivam 2019 + + - - +
Bhat 2003 ? ? ? ? +
Einloft 2015 + - - - -
El Sakka 2016 ? ? - - -
Faerk 2000 ? ? ? ? -
Gathwala 2012 + ? ? ? +
Gross 1987 (1) ? ? ? ? +
Gross 1987 (2) ? ? ? ? +
Gupta 2018 + + - - +
Lucas 1996 + + - - +
Modanlou 1986 ? ? - - -
Mukhopadhyay 2007 + ? ? ? +
Nicholl 1999 ? + - - +
Pettifor 1989 ? ? ? ? -
Polberger 1989 ? ? ? ? -
Porcelli 1992 ? ? ? ? +
Wauben 1998 + ? - - -
Zuckerman 1994 - - - ? +
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Allocation
Risk of selection bias was largely "unclear". Seven trials described
adequate methods of random sequence generation (Lucas 1996;
Wauben 1998; Mukhopadhyay 2007; Gathwala 2012; EinloT 2015;
Gupta 2018; Adhisivam 2019). Four explicitly described adequate
allocation concealment methods (Lucas 1996; Nicholl 1999; Gupta
2018; Adhisivam 2019). Zuckerman 1994 was at high risk of
selection bias, as investigators performed group allocation in a
quasi-randomised fashion (odd and even hospital numbers).
Blinding
Nine trials were known to be at high risk of performance and
selection bias as reports stated that personnel and outcome
assessors were not masked (Modanlou 1986; Zuckerman 1994;
Lucas 1996; Wauben 1998; Nicholl 1999; EinloT 2015; El Sakka 2016;
Gupta 2018; Adhisivam 2019). Risk of performance and selection
bias was "unclear" in the other trial reports.
Incomplete outcome data
We judged seven trials to be at high risk of attrition bias (Modanlou
1986; Pettifor 1989; Polberger 1989; Wauben 1998; Faerk 2000;
EinloT 2015; El Sakka 2016), and the other trials to be at low risk.
Other potential sources of bias
Authors of three trial reports were employees of the manufacturer
of the fortifier used (Modanlou 1986; Lucas 1996; Wauben 1998).
The manufacturer of the fortifier funded three trials (Pettifor 1989;
Lucas 1996; EinloT 2015).
E8ects of interventions
See: Summary of findings 1 Multi-nutrient fortification of human
milk for preterm infants
Growth rates (Outcomes 1.1 to 1.6)
Weight gain (Analysis 1.1). Meta-analysis of data from 14 trials
including 951 infants showed a higher rate of weight gain in
the intervention (fortifier) group (mean diHerence (MD) 1.76,
95% confidence interval (CI) 1.30 to 2.22 g/kg/d). Moderate
heterogeneity was present in this analysis (I2 = 65%) (Figure 3). This
was not explained in sensitivity analyses. The funnel plot was not
asymmetrical. We assessed the certainty of evidence as "low" using
GRADE methods, downgraded for risk of bias in included trials and
for unexplained heterogeneity in the meta-analysis (Summary of
findings 1).
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Figure 3.   Forest plot of comparison: 1 Fortified breast milk versus unfortified breast milk, outcome: 1.1 Weight gain
(g/kg/d).
Study or Subgroup
1.1.1 All trials
Modanlou 1986
Gross 1987 (1)
Gross 1987 (2)
Polberger 1989
Pettifor 1989
Porcelli 1992
Lucas 1996
Wauben 1998
Nicholl 1999
Mukhopadhyay 2007
Einloft 2015
El Sakka 2016
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 37.16, df = 13 (P = 0.0004); I² = 65%
Test for overall effect: Z = 7.52 (P < 0.00001)
1.1.2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986
Polberger 1989
Pettifor 1989
Nicholl 1999
Mukhopadhyay 2007
Einloft 2015
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 23.18, df = 7 (P = 0.002); I² = 70%
Test for overall effect: Z = 6.67 (P < 0.00001)
1.1.3 Trials conducted in low- or middle-income countries
Pettifor 1989
Mukhopadhyay 2007
Einloft 2015
El Sakka 2016
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 6.44, df = 5 (P = 0.27); I² = 22%
Test for overall effect: Z = 5.40 (P < 0.00001)
1.1.4 Trials using preterm formula powder as fortifier
Gross 1987 (2)
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 2.38, df = 2 (P = 0.30); I² = 16%
Test for overall effect: Z = 5.11 (P < 0.00001)
Test for subgroup differences: Chi² = 1.85, df = 3 (P = 0.60), I² = 0%
Fortified
Mean
26.7
19.9
21.5
20.4
16.7
11.4
15.6
16.6
15.1
15.1
19.2
16.8
18
9.4
26.7
20.4
16.7
15.1
15.1
19.2
16.8
18
16.7
15.1
19.2
16.8
18
9.4
21.5
16.8
18
SD
3.4
2.5
3.5
2.8
5
2.7
4.7
1.6
3.3
4
4.3
5.5
2.9
2.2
3.4
2.8
5
3.3
4
4.3
5.5
2.9
5
4
4.3
5.5
2.9
2.2
3.5
5.5
2.9
Total
8
10
17
7
29
10
137
12
13
82
19
25
75
40
484
8
7
29
13
82
19
25
75
258
29
82
19
25
75
40
270
17
25
75
117
Unfortified
Mean
19.4
17.7
17.5
15.3
16.8
12
15
14.2
13.2
12.9
19.9
13.8
16.1
7.9
19.4
15.3
16.8
13.2
12.9
19.9
13.8
16.1
16.8
12.9
19.9
13.8
16.1
7.9
17.5
13.8
16.1
SD
2.7
4.4
3.3
3.2
6.4
3
3.5
2
6.4
4
3.7
4.7
2.9
4.8
2.7
3.2
6.4
6.4
4
3.7
4.7
2.9
6.4
4
3.7
4.7
2.9
4.8
3.3
4.7
2.9
Total
10
10
9
7
28
10
138
13
10
75
19
25
73
40
467
10
7
28
10
75
19
25
73
247
28
75
19
25
73
40
260
9
25
73
107
Weight
2.5%
2.1%
2.8%
2.1%
2.4%
3.4%
21.9%
10.5%
1.1%
13.4%
3.2%
2.6%
24.1%
7.9%
100.0%
4.9%
4.1%
4.6%
2.2%
26.1%
6.3%
5.1%
46.8%
100.0%
4.4%
25.0%
6.0%
4.9%
45.0%
14.7%
100.0%
9.6%
8.9%
81.5%
100.0%
Mean Difference
IV, Fixed, 95% CI
7.30 [4.41 , 10.19]
2.20 [-0.94 , 5.34]
4.00 [1.28 , 6.72]
5.10 [1.95 , 8.25]
-0.10 [-3.09 , 2.89]
-0.60 [-3.10 , 1.90]
0.60 [-0.38 , 1.58]
2.40 [0.99 , 3.81]
1.90 [-2.45 , 6.25]
2.20 [0.95 , 3.45]
-0.70 [-3.25 , 1.85]
3.00 [0.16 , 5.84]
1.90 [0.97 , 2.83]
1.50 [-0.14 , 3.14]
1.76 [1.30 , 2.22]
7.30 [4.41 , 10.19]
5.10 [1.95 , 8.25]
-0.10 [-3.09 , 2.89]
1.90 [-2.45 , 6.25]
2.20 [0.95 , 3.45]
-0.70 [-3.25 , 1.85]
3.00 [0.16 , 5.84]
1.90 [0.97 , 2.83]
2.18 [1.54 , 2.81]
-0.10 [-3.09 , 2.89]
2.20 [0.95 , 3.45]
-0.70 [-3.25 , 1.85]
3.00 [0.16 , 5.84]
1.90 [0.97 , 2.83]
1.50 [-0.14 , 3.14]
1.73 [1.10 , 2.35]
4.00 [1.28 , 6.72]
3.00 [0.16 , 5.84]
1.90 [0.97 , 2.83]
2.20 [1.36 , 3.04]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours control Favours fortified
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Length gain (Analysis 1.2). Meta-analysis of data from 10 trials
including 741 infants showed a higher rate of length gain in
the intervention group (MD 0.11, 95% CI 0.08 to 0.15 cm/week).
Moderate heterogeneity was present in this analysis (I2 = 69%)
(Figure 4). This was not explained in sensitivity analyses. The funnel
plot was not asymmetrical. We assessed the certainty of evidence
as "low" using GRADE methods, downgraded for risk of bias in
included trials and for unexplained heterogeneity in meta-analysis
(Summary of findings 1).
 
Figure 4.   Forest plot of comparison: 1 Fortified breast milk versus unfortified breast milk, outcome: 1.2 Length gain
(cm/week).
Study or Subgroup
1.2.1 All trials
Modanlou 1986
Gross 1987 (2)
Gross 1987 (1)
Polberger 1989
Porcelli 1992
Lucas 1996
Wauben 1998
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 29.00, df = 9 (P = 0.0006); I² = 69%
Test for overall effect: Z = 5.67 (P < 0.00001)
1.2.2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986
Polberger 1989
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 14.21, df = 4 (P = 0.007); I² = 72%
Test for overall effect: Z = 6.20 (P < 0.00001)
1.2.3 Trials conducted in low- or middle-income countries
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 8.14, df = 2 (P = 0.02); I² = 75%
Test for overall effect: Z = 5.20 (P < 0.00001)
1.2.4 Trials using preterm formula powder as fortifier
Gross 1987 (2)
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 2.28 (P = 0.02)
Test for subgroup differences: Chi² = 4.41, df = 3 (P = 0.22), I² = 32.0%
Fortified
Mean
0.99
0.84
0.89
1.2
0.6
0.93
1.1
1.04
1.2
1.04
0.99
1.2
1.04
1.2
1.04
1.04
1.2
1.04
0.84
1.04
SD
0.4
0.25
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0.17
0.2
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0.2
0.3
0.5
0.21
0.4
0.17
0.3
0.5
0.21
0.3
0.5
0.21
0.25
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Total
8
17
10
7
10
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12
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19
75
377
8
7
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19
75
191
82
19
75
176
17
75
92
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Mean
0.81
0.79
0.81
0.83
0.7
0.96
0.9
0.86
0.8
0.96
0.81
0.83
0.86
0.8
0.96
0.86
0.8
0.96
0.79
0.96
SD
0.44
0.12
0.22
0.17
0.3
0.47
0.2
0.2
0.2
0.23
0.44
0.17
0.2
0.2
0.23
0.2
0.2
0.23
0.12
0.23
Total
10
9
10
7
10
138
13
75
19
73
364
10
7
75
19
73
184
75
19
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167
9
73
82
Weight
1.0%
7.8%
4.9%
5.0%
3.2%
12.8%
6.4%
25.1%
2.7%
31.2%
100.0%
1.6%
7.6%
38.6%
4.1%
48.0%
100.0%
42.6%
4.5%
52.9%
100.0%
19.9%
80.1%
100.0%
Mean Difference
IV, Fixed, 95% CI
0.18 [-0.21 , 0.57]
0.05 [-0.09 , 0.19]
0.08 [-0.10 , 0.26]
0.37 [0.19 , 0.55]
-0.10 [-0.32 , 0.12]
-0.03 [-0.14 , 0.08]
0.20 [0.04 , 0.36]
0.18 [0.10 , 0.26]
0.40 [0.16 , 0.64]
0.08 [0.01 , 0.15]
0.11 [0.08 , 0.15]
0.18 [-0.21 , 0.57]
0.37 [0.19 , 0.55]
0.18 [0.10 , 0.26]
0.40 [0.16 , 0.64]
0.08 [0.01 , 0.15]
0.16 [0.11 , 0.20]
0.18 [0.10 , 0.26]
0.40 [0.16 , 0.64]
0.08 [0.01 , 0.15]
0.14 [0.09 , 0.19]
0.05 [-0.09 , 0.19]
0.08 [0.01 , 0.15]
0.07 [0.01 , 0.14]
Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours control Favours fortified
 
Head growth (Analysis 1.3). Meta-analysis of data from 11 trials
including 821 infants showed a higher rate of head growth in the
intervention group (MD 0.06, 95% CI 0.03 to 0.08 cm/week). We
detected low heterogeneity in this analysis (I2 = 42%) (Figure 5).
The funnel plot was not asymmetrical. We assessed the certainty
of evidence as "moderate" using GRADE methods, downgraded for
risk of bias in included trials (Summary of findings 1).
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Figure 5.   Forest plot of comparison: 1 Fortified breast milk versus unfortified breast milk, outcome: 1.3 Head
growth (cm/week).
Study or Subgroup
1.3.1 All trials
Modanlou 1986
Gross 1987 (2)
Gross 1987 (1)
Polberger 1989
Porcelli 1992
Lucas 1996
Wauben 1998
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 17.26, df = 10 (P = 0.07); I² = 42%
Test for overall effect: Z = 4.01 (P < 0.0001)
1.3.2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986
Polberger 1989
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 13.08, df = 4 (P = 0.01); I² = 69%
Test for overall effect: Z = 3.66 (P = 0.0003)
1.3.3 Trials conducted in low- or middle-income countries
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 6.45, df = 3 (P = 0.09); I² = 53%
Test for overall effect: Z = 2.55 (P = 0.01)
1.3.4 Trials using preterm formula powder as fortifier
Gross 1987 (2)
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 1.08, df = 1 (P = 0.30); I² = 8%
Test for overall effect: Z = 1.92 (P = 0.06)
Test for subgroup differences: Chi² = 1.25, df = 3 (P = 0.74), I² = 0%
Fortified
Mean
1.09
0.84
0.92
1.11
0.7
1.01
1
0.83
0.91
0.97
0.56
1.09
1.11
0.83
0.91
0.97
0.83
0.91
0.97
0.56
0.84
0.97
SD
0.07
0.21
0.09
0.13
0.3
0.47
0.1
0.2
0.21
0.19
0.1
0.07
0.13
0.2
0.21
0.19
0.2
0.21
0.19
0.1
0.21
0.19
Total
8
17
10
7
10
137
12
82
19
75
40
417
8
7
82
19
75
191
82
19
75
40
216
17
75
92
Unfortified
Mean
0.82
0.84
0.83
0.94
0.7
0.95
0.9
0.75
0.98
0.9
0.54
0.82
0.94
0.75
0.98
0.9
0.75
0.98
0.9
0.54
0.84
0.9
SD
0.24
0.09
0.16
0.25
0.2
0.35
0.2
0.2
0.14
0.2
0.16
0.24
0.25
0.2
0.14
0.2
0.2
0.14
0.2
0.16
0.09
0.2
Total
10
9
10
7
10
138
13
75
19
73
40
404
10
7
75
19
73
184
75
19
73
40
207
9
73
82
Weight
3.2%
5.8%
6.0%
1.8%
1.6%
8.1%
5.2%
19.9%
6.0%
19.7%
22.8%
100.0%
6.3%
3.5%
39.3%
12.0%
39.0%
100.0%
29.0%
8.8%
28.8%
33.3%
100.0%
22.8%
77.2%
100.0%
Mean Difference
IV, Fixed, 95% CI
0.27 [0.11 , 0.43]
0.00 [-0.12 , 0.12]
0.09 [-0.02 , 0.20]
0.17 [-0.04 , 0.38]
0.00 [-0.22 , 0.22]
0.06 [-0.04 , 0.16]
0.10 [-0.02 , 0.22]
0.08 [0.02 , 0.14]
-0.07 [-0.18 , 0.04]
0.07 [0.01 , 0.13]
0.02 [-0.04 , 0.08]
0.06 [0.03 , 0.08]
0.27 [0.11 , 0.43]
0.17 [-0.04 , 0.38]
0.08 [0.02 , 0.14]
-0.07 [-0.18 , 0.04]
0.07 [0.01 , 0.13]
0.07 [0.03 , 0.11]
0.08 [0.02 , 0.14]
-0.07 [-0.18 , 0.04]
0.07 [0.01 , 0.13]
0.02 [-0.04 , 0.08]
0.04 [0.01 , 0.08]
0.00 [-0.12 , 0.12]
0.07 [0.01 , 0.13]
0.05 [-0.00 , 0.11]
Mean Difference
IV, Fixed, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours control Favours fortified
 
Weight at 12 to 18 months (Analysis 1.4). We obtained data from
Lucas 1996 and Wauben 1998 (270 infants). Neither trial nor a meta-
analysis of their data showed an eHect (MD -0.03, 95% CI -0.31 to
0.25 kg).
Length at 12 to 18 months (Analysis 1.5). We obtained data from
Lucas 1996 and Wauben 1998 (270 infants). Neither trial nor a meta-
analysis of their data showed an eHect (MD -0.19, 95% CI -0.98 to
0.60 cm).
Head circumference at 12 to 18 months (Analysis 1.6). We obtained
data from Lucas 1996 and Wauben 1998 (270 infants). Neither trial
nor a meta-analysis of their data showed an eHect (MD -0.10, 95%
CI -0.37 to 0.18 cm).
Neurodevelopmental outcomes aKer 12 months of age
(Outcomes 1.7 and 1.8)
One trial (245 infants) reported data (Lucas 1996). This trial showed
no statistically significant diHerences in:
• mental development index at 18 months (Analysis 1.7): MD 2.20
(95% CI -3.35 to 7.75); or
• psychomotor development index at 18 months (Analysis 1.8):
MD 2.40 (95% CI -1.90 to 6.70).
We assessed the certainty of evidence as "moderate" using GRADE
methods, downgraded for imprecision of estimates of eHect
(Summary of findings 1).
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Length of hospital stay in weeks (Outcome 1.9)
Meta-analysis of data from six trials including 526 infants did not
show a diHerence (MD -0.07, 95% CI -0.35 to 0.21 weeks; Analysis
1.9).
Feed intolerance (Outcome 1.10)
Meta-analysis of data from seven trials including 453 infants did not
show an eHect (typical RR 1.05, 95% CI 0.65 to 1.67; Analysis 1.10).
Necrotising enterocolitis (Outcome 1.11)
Meta-analysis of data from 13 trials including 1110 infants did
not show an eHect (typical RR 1.37, 95% CI 0.72 to 2.63; Analysis
1.11). Low heterogeneity was present in this analysis (I2 = 0%). We
assessed the certainty of evidence as "low" using GRADE methods,
downgraded for high risk of bias in most trials and for imprecision
of estimates of eHect (Summary of findings 1).
Measures of bone mineralisation (Outcomes 1.12 and 1.13)
Serum alkaline phosphatase (Analysis 1.12). Meta-analysis of
data obtained from six trials (restricted to trials without
mineral supplementation of the control group) showed that
the intervention group had lower serum alkaline phosphatase
(ALP) levels (Modanlou 1986; Pettifor 1989; Zuckerman 1994;
Mukhopadhyay 2007; Gathwala 2012; EinloT 2015): weighted
mean diHerence (WMD) -142 (95% CI -204 to -80) IU/L. Moderate
heterogeneity was present in this analysis (I2 = 60%). Bhat 2003
did not report peak ALP levels but did state that the intervention
group included fewer infants who developed high ALP levels (>
450 IU/L) than were included in the control group (without mineral
supplementation).
Bone mineral content (Analysis 1.13). Only Pettifor 1989 provided
numerical data and reported higher bone mineral content in
the intervention group: WMD 12.0 (95% CI 6.3 to 17.7) mg/cm.
Modanlou 1986, Gross 1987 (1), and Gross 1987 (2) detected no
statistically significant diHerences between control and treatment
groups but did not report numerical data for inclusion in meta-
analyses.
Measures of metabolic health for long-term follow-up
None of the trials reported these measures.
Subgroup analyses
Very preterm or VLBW infants
Meta-analyses of data from trials that restricted participation to
very preterm or VLBW infants showed no diHerences in the meta-
analyses of all trial data (Analysis 1.1; Analysis 1.2; Analysis 1.3;
Analysis 1.9; Analysis 1.10; Analysis 1.11; Analysis 1.12; Analysis
1.13).
Fortifcation of donor breast milk
One trial used donor milk exclusively (Adhisivam 2019). Seven trials
supplemented mother's own milk with donor milk (Gross 1987
(1); Gross 1987 (2); Polberger 1989; Porcelli 1992; Nicholl 1999;
Faerk 2000; Mukhopadhyay 2007). Outcome data for infants fed
with donor breast milk exclusively were not available to include in
subgroup meta-analyses with Adhisivam 2019.
Trials using fortifier extracted from human milk (rather than
cow's milk-based fortifiers)
All trials included in this review used cow's milk-based fortifiers.
Trials using infant formula as the multi-nutrient fortifier
Gross 1987 (2) (for a subset of the intervention group); Zuckerman
1994; El Sakka 2016; and Gupta 2018 used preterm infant formula
powder to fortify breast milk.
Growth parameters (Analysis 1.1; Analysis 1.2; Analysis 1.3). Meta-
analysis of date from Gross 1987 (2) and Gupta 2018 showed pooled
eHects consistent with the overall meta-analyses (Figure 3; Figure
4; Figure 5).
Length of hospital stay (Analysis 1.9). Meta-analysis of date from
Zuckerman 1994; El Sakka 2016; and Gupta 2018 showed pooled
eHects consistent with the overall meta-analysis.
Necrotising enterocolitis (Analysis 1.11). Meta-analysis of date from
Zuckerman 1994 and Gupta 2018 showed pooled eHects consistent
with the overall meta-analysis.
Serum level of ALP (Analysis 1.12). Analysis of data from Zuckerman
1994 showed an eHect consistent with the overall meta-analysis.
Trials conducted in low- and middle-income countries
Eight trials were conducted in middle-income countries: Pettifor
1989 and Zuckerman 1994 in South Africa (upper middle-
income country), El Sakka 2016 in Egypt (lower middle-income
country), EinloT 2015 in Brazil (upper middle-income country), and
Mukhopadhyay 2007; Gathwala 2012; Gupta 2018; and Adhisivam
2019 in India (lower middle-income country). Meta-analyses
showed no significant diHerences from the meta-analyses of all
trials together (Analysis 1.1; Analysis 1.2; Analysis 1.3; Analysis 1.9;
Analysis 1.10; Analysis 1.11; Analysis 1.12; Analysis 1.13).
D I S C U S S I O N
Summary of main results
Evidence from 18 randomised controlled trials shows that multi-
nutrient fortification results in modest increases in in-hospital rates
of weight gain, length gain, and head growth for preterm infants.
Few data are available for growth and developmental outcomes
assessed beyond infancy, and these show no eHects of fortification.
None of the trials has reported data related to possible longer-term
"programmed" metabolic or physiological consequences of multi-
nutrient supplementation in early infancy.
Meta-analysis of data from trials that included a control group
without bone mineral supplementation showed that multi-nutrient
fortification reduces serum alkaline phosphatase (ALP) levels but
provided limited evidence of eHects on other measures of bone
mineralisation or health. This review found no consistent evidence
of other benefits or harms of multi-nutrient fortification, including
no data to suggest that fortification increases the risk of feed
intolerance or necrotising enterocolitis in preterm infants.
Overall completeness and applicability of evidence
We recommend cautious interpretation and application of these
findings. Although meta-analyses indicate that multi-nutrient
fortification increases rates of growth, typical eHect sizes are small.
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Over the course of four weeks, multi-nutrient fortification for a
very preterm infant weighing 1 kg at birth would result in an extra
50 g of weight gain, 4 mm of length gain, and 2 mm of head
circumference gain. The clinical importance of these eHects on in-
hospital growth rates is unclear, and uncertainty remains about the
long-term impact on growth or development. Similarly, although
multi-nutrient fortification that includes minerals (versus human
breast milk without added minerals) reduces the serum ALP level,
this is an insensitive measure of bone mineralisation or health
(Tinnion 2012). In current clinical practice, mineral supplements
(mainly phosphate) are available for infants at high risk of, or with
biochemical or other features of, metabolic bone disease.
Meta-analyses of growth outcomes showed heterogeneity that was
not explained by major diHerences in trial design or conduct.
Participants in these trials were similar (mostly stable very low
birth weight (VLBW) infants). Although we noted some variation in
the types of fortifier used, the overall target level of fortification
and the duration of administration were similar. Most trials
aimed to provide extra protein and non-protein energy by adding
a powdered, commercially available, multi-nutrient fortifier to
breast milk to attain about 80 kcal/100 mL and about 2.0 to
2.6 g of protein/100 mL (plus proportionate supplements of
minerals, vitamins, and trace elements). This approach aims to
maintain optimal protein-to-energy ratios to ensure that the
protein contributed to growth and was not catabolised as a fuel
source (Kashyap 1994). These total levels of protein and energy,
however, are at the lower bounds of currently recommended
intakes needed to match intrauterine accretion (based on receiving
about 150 mL/kg/d of milk), and this is a possible explanation for
the modest impact of the intervention on growth parameters.
A major limitation of this review is that most included trials were
undertaken at healthcare facilities in high-income countries, and
few were conducted in community settings or in middle- or low-
income countries. Reported evidence therefore may be of limited
use to inform care practice in the resource-limited settings where
most preterm and low birth weight infants are cared for globally
(Imdad 2013).
Quality of the evidence
We assessed the certainty of evidence as low or moderate for
most outcomes (Summary of findings 1). Included trials were
generally small and had methodological quality weaknesses,
including inadequate measures to conceal random allocation and
incomplete follow-up assessment during the intervention period.
Masking of clinicians, parents, and caregivers was not possible
given the nature of the intervention, but this is not likely to
be a major source of bias in growth assessments. Knowledge of
the intervention group may have aHected caregivers' or mothers'
perceptions and views of feeding, and it may have influenced
decisions on whether any formula should be given as a supplement
to (or instead of) breast milk. These trials did not examine whether
multi-nutrient fortification aHected the mother's commitment to
establish breastfeeding, or whether diHerences were noted in the
proportion of infants receiving any breast milk at the end of the
intervention period.
Potential biases in the review process
Our main concern with the review process is the possibility
that findings may be subject to publication and other reporting
biases. We attempted to minimise this threat by screening the
reference lists of included trials and related reviews and searching
the proceedings of major international perinatal conferences to
identify trial reports that are not (or are not yet) published in full
form in academic journals. The meta-analyses that we performed
did not contain suHicient trials to explore symmetry of funnel plots
as a means of identifying possible publication or reporting bias.
Agreements and disagreements with other studies or
reviews
These findings are broadly consistent with those of another
Cochrane Review, which showed that preterm infants who received
nutrient-enriched formula (similar energy and protein levels
to multi-nutrient fortified human breast milk) versus standard
formula (similar energy and protein levels to unfortified human
breast milk) had higher in-hospital rates of weight gain (mean
diHerence (MD) 2.43 g/kg/d, 95% confidence interval (CI) 1.60 to
3.26), length gain (MD 0.02 cm/week, 95% CI -0.07 to 0.11), and head
circumference growth (MD 0.1 cm/week, 95% CI 0.02 to 0.19) (Walsh
2019).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Multi-nutrient fortification of human milk is associated with small,
short-term increases in weight gain and in linear and head growth.
There is no evidence to suggest that these short-term gains lead
to any long-term eHects on growth or development. Investigators
reported no increase in adverse eHects among infants who received
multi-nutrient fortifiers, although the total number of infants
studied was small and the data that could be abstracted from
published studies were limited.
Implications for research
Given the potential for multi-nutrient fortification of breast milk
to aHect important outcomes in preterm infants, this intervention
merits further assessment. As this practice is already widely
established and accepted as a standard of care in many neonatal
units, it is important for researchers to determine whether mothers
and clinicians would support a trial of this intervention. All trials
should be powered to detect potentially important eHects on
growth rates, as well as potential adverse consequences, during
infancy and beyond. Trials should attempt to ensure that caregivers
and assessors are blind to the intervention. Although this goal
is more easily achievable for longer-term assessments, it is also
important for ascertainment of adverse events, such as feeding
intolerance and necrotising enterocolitis, when the threshold for
investigation or diagnosis may be aHected by knowledge of the
intervention. We have identified one such planned trial (Mills 2015).
New research areas
Most commercially available fortifiers contain protein,
carbohydrate, calcium, phosphate, other minerals (zinc,
manganese, magnesium, and copper), vitamins, and electrolytes.
Investigators have not evaluated the benefits of many of these
individual components in a controlled manner. Future research
could compare diHerent proprietary preparations to evaluate both
short-term and long-term outcomes and adverse eHects, while
searching for the "optimal" composition of fortifiers. Investigators
could examine the eHects of targeted or adjustable fortification to
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determine whether human milk-based fortifier provides any cost-
eHective advantages over cow's milk-based fortifier.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Randomised controlled trial
Participants 80 "healthy" preterm infants (average gestational age at birth = 32 weeks, average birth weight 1400 g)
Exclusion criteria: major congenital anomalies, surgical problems of the gastrointestinal tract, birth as-
phyxia, and early-onset sepsis
Setting: Department of Neonatology, Jawaharlal Institute of Postgraduate Medical Education and Re-
search, Puducherry, India
Interventions Intervention (N = 40): fortified donor human milk (4 g of commercially available powdered fortifier per
100 mL of milk, resulting in extra 2 g of protein and 13.3 kcal per 100 mL)
Control (N = 40): donor human milk without fortifier
Outcomes • Necrotising enterocolitis
• Rate of weight gain and head circumference growth
• Duration of hospital stay
Notes All participants received multi-vitamin and iron supplements
Human milk was enriched with a fortifier when infants reached an intake volume of 100 mL/kg/d
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Study authors report use of "computer-generated random numbers"
Allocation concealment
(selection bias)
Low risk Study authors report use of "opaque sealed envelopes"
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Study was described as "unblinded"
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Study was described as "unblinded"
Adhisivam 2019 
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Incomplete outcome data
(attrition bias)
All outcomes
Low risk All randomised infants have been included for intention-to-treat analyses
Adhisivam 2019  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 100 VLBW infants
Exclusion criterion: need for prolonged mechanical ventilation
Setting: Special Care Baby Unit, Khoula Hospital, Muscat, Oman
Interventions Intervention (N = 50): fortified human milk (4 g of powdered fortifier to achieve 81 kcal, 2.4 g protein,
and 9.0 g carbohydrates per 100 mL of milk)
Control (N = 50): human milk only
If amounts were insufficient, human milk was supplemented with formula up to a maximum of 15% of
energy for 2 days. Babies who required supplementation beyond this were excluded from the study
Outcomes • Weight gain
• Markers of nutritional and bone mineral status
• Adverse events including necrotising enterocolitis
Notes Human milk was enriched with a fortifier when infants received 140 mL/kg/d
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Report states that infants were "randomly assigned", but method of sequence
generation is not described
Allocation concealment
(selection bias)
Unclear risk No details were reported
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk Study was described as "double-blind", but it was not specified who was blind-
ed
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Study was described as "double-blind", but it was not specified who was blind-
ed
Incomplete outcome data
(attrition bias)
All outcomes
Low risk No details of infants lost to follow-up were reported. Lack of attrition bias was
assumed
Bhat 2003 
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Study characteristics
Methods Randomised controlled trial
Participants 83 VLBW infants (average gestational age at birth = 29.7 weeks, average birth weight 1160 g)
Exclusion criteria: acute or chronic disease, including congenital malformations, heart or neurologic
disease, or inborn errors of metabolism; and newborns undergoing surgery or using diuretics and corti-
costeroids
• NB. Randomised participants were excluded retrospectively if they (a) received parenteral nutrition for
longer than 10 days or used mechanical ventilation, (b) received continuous positive airway pressure or
supplemental oxygen, (c) developed any serious condition such as necrotising enterocolitis or sepsis, (d)
did not undergo densitometry at discharge, or (e) did not reach a minimum volume of 50% of human
milk during the study period (i.e. fed premature infant formula)
Setting: Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil
Interventions Intervention (N = 41): fortified maternal milk (5 g of commercially available powdered fortifier per 100
mL of milk, resulting in extra 1 g of protein and 17 kcal per 100 mL)
Control (N = 42): maternal milk without fortifier
Outcomes • Bone mineral content (DEXA scan) when infant weight = 2000 g
• Rate of weight gain, length gain, and head circumference growth
• Duration of hospital stay
Notes All participants received multi-vitamin and iron supplements enterally (but not minerals)
Funded by Nestle
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated sequence
Allocation concealment
(selection bias)
High risk Report states that participants were "randomly assigned", but "no allocation
concealment" was used
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Study was described as "unblinded"
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Study was described as "unblinded"
Incomplete outcome data
(attrition bias)
All outcomes
High risk Forty-five infants (22 in the supplemented group and 23 in the unsupplement-
ed group) were excluded from the study after randomisation. Reasons for ex-
clusion were reported: "After hospital discharge, retrospective exclusions result-
ed in a total sample of 38 newborns who were included in the analysis (supple-
mented group, N = 19; control group, N = 19)"
EinloK 2015 
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Study characteristics
Methods Randomised controlled trial
Participants 59 preterm VLBW infants (average gestational age at birth = 32 weeks, average birth weight 1292 g)
Exclusion criteria: congenital abnormalities, intolerance to enteral feeds, hyperbilirubinaemia requir-
ing phototherapy, hypoglycaemia, hyponatraemia, or respiratory illness necessitating any kind of as-
sisted ventilation; or mothers with contraindication to breastfeeding
Setting: Department of Neonatology, Faculty of Medicine, AinShams University, Cairo, Egypt
Interventions Intervention (N = 29): maternal milk fortified with "post-discharge formula" powder (to achieve esti-
mated average 83 kcal, 1.45 g protein, and 8.7 g carbohydrates per 100 mL of milk)
Control (N = 30): maternal milk without fortifier
Outcomes • Feed intolerance (necrotising enterocolitis not reported)
• Rate of weight gain and head circumference growth
• Duration of hospital stay
Notes All participants received vitamin D and iron supplements
Human milk was enriched with post-discharge formula powder when infants reached an intake volume
of 100 mL/kg/d and continued until infant weight = 1800 g
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Report states that infants were "randomly categorized", but the method of se-
quence generation is not described
Allocation concealment
(selection bias)
Unclear risk No details were reported
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Study was likely to be unblinded
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Study was likely to be unblinded
Incomplete outcome data
(attrition bias)
All outcomes
High risk Post-randomisation exclusion of 9/59 (15%) participants
El Sakka 2016 
 
 
Study characteristics
Methods Randomised controlled trial
Participants 103 very preterm infants
Faerk 2000 
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Exclusion criterion: major congenital anomaly
Setting: NICUs, Rigshospitalet and Hvidovre Hospital, Copenhagen, Denmark
Interventions Intervention (N = 51): human milk (maternal or donor) supplemented with 0.4 g protein, 1.4 g carbohy-
drate, 35 mg calcium, and 17 mg phosphorus per 100 mL (Milupa Eoprotin)
Control (N = 52): maternal or donor milk supplemented with 10 mg phosphate per 100 mL
Outcomes • Weight, length, and head circumference at term
• Measures of bone mineralisation (DEXA scan)
• Necrotising enterocolitis
Notes Target intake of 200 mL/kg/d
All infants received vitamin D 800 IU per day
Intervention ceased when breastfed or at 36 weeks' postmenstrual age
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of sequence generation is not described
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk Study is described as "double-blind", but it is not specified who was blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Study is described as "double-blind", but it is not specified who was blinded
Incomplete outcome data
(attrition bias)
All outcomes
High risk 103 infants were randomised, but outcome data were reported for only 76
(74%) because of loss to follow-up or technical problems with DEXA scans. Fur-
ther information about outcomes was not available from investigators
Faerk 2000  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 67 consecutive preterm infants of birth weight < 1800 g
Eligibility criteria: healthy preterm infants, appropriate for gestational age, no birth asphyxia, enterally
fed with breast milk by 14 days of life, no congenital malformations, no ventilatory support previous 7
days, no diuretic or steroid therapy
Setting: Neonatology Unit, Department of Paediatrics, Pt. B.D. Sharma PGIMS, Rohtak, India
Interventions Intervention (N = 34): breast milk fortified with Lactodex Human Milk Fortifier (to achieve 80 kcal, 9.4 g
carbohydrate, and 2.2 g protein per 100 mL, plus minerals and electrolytes)
Gathwala 2012 
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Control (N = 33): unfortified breast milk
Infants were excluded from the study if they needed more than 25% of their daily requirements to be
provided by formula or other milk
Outcomes • Time to regain birth weight
• Time to reach 2200 g
• Duration of hospital stay
• Biochemical markers of nutritional status (including serum ALP)
Notes Incidence of feed intolerance or necrotising enterocolitis is not reported
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Use of a random numbers table
Allocation concealment
(selection bias)
Unclear risk Details of allocation concealment are not reported
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk It is not reported whether personnel were blinded (participant blinding irrele-
vant in this context)
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk It is not reported whether outcome assessors were blinded
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Four babies in the intervention group and 3 in the control group were excluded
post randomisation, as their need for additional milk exceeded 25%. These in-
fants were not included in intention-to-treat analyses
Gathwala 2012  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial (2-phase trial, referred to as Gross 1987 (1) and Gross 1987 (2))
Participants 20 infants with birth weight < 1600 g
Eligibility criteria: birth weight appropriate for gestational age, free from congenital anomaly or major
disease, breathing room air, ability to begin enteral feeding within first week after birth
Setting: Duke University Medical Center, Durham, North Carolina, USA
Interventions Intervention (N = 10): human milk mixed with preterm infant formula Similac Special Care (Ross Labo-
ratories) containing 1.8 g protein per 100 mL, as well as carbohydrate
Control (N = 10): human milk with no supplementation
Feeding of human milk supplemented with formula commenced after 1 week of enteral feeds of unfor-
tified human milk. All infants received intravenous dextrose and electrolytes until day 5 of feeding. All
infants received supplemental vitamins with their milk from day 8 of feeding
Outcomes • In-hospital growth parameters
Gross 1987 (1) 
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• Growth at 44 weeks' postmenstrual age
• Bone mineral content and biochemical indices of bone metabolism
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Details of sequence generation are not reported. Report states that infants
were "assigned randomly" to receive fortified or unfortified breast milk
Allocation concealment
(selection bias)
Unclear risk Report states that "sealed envelopes" were used, but it is unclear whether
these were sequentially numbered and opaque
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk It is not reported whether personnel were blinded (participant blinding is irrel-
evant in this context)
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk It is not reported whether outcome assessors were blinded
Incomplete outcome data
(attrition bias)
All outcomes
Low risk No details of infants lost to follow-up are reported. Lack of attrition bias is as-
sumed
Gross 1987 (1)  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial (2-phase trial, referred to as Gross 1987 (1) and Gross 1987 (2))
Participants 30 infants with birth weight < 1600 g
Eligibility criteria: birth weight appropriate for gestational age, free from congenital anomaly or major
disease, breathing room air, ability to begin enteral feeding within first week after birth
Setting: Boston Perinatal Center, Boston, Massachusetts, USA
Interventions Intervention 1 (N = 11): human milk mixed with preterm infant formula Similac Special Care (Ross Labo-
ratories) containing 1.8 g protein per 100 mL, as well as carbohydrate (as above for Gross 1987 (1))
Intervention 2 (N = 10): human milk mixed with powdered breast milk fortifier
Control (N = 9): human milk with no supplementation
Fortification with the powdered fortifier was introduced after 2 weeks of enteral feeds of unfortified hu-
man milk. All infants received intravenous dextrose and electrolytes until day 5 of feeding. All infants
received supplemental vitamins with their milk from day 8 of feeding. For this review, participants from
the 2 intervention groups were taken together as infants receiving fortification
Outcomes • In-hospital growth parameters
• Growth at 44 weeks' postmenstrual age
• Bone mineral content and biochemical indices of bone metabolism
Gross 1987 (2) 
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Notes The full composition of powdered fortifier is not reported in the paper. We deemed it appropriate for
inclusion as powdered formula appeared to include protein and energy, as required by our inclusion
criteria
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Details of sequence generation are not reported. Report states that infants
were "assigned randomly" to receive fortified or unfortified breast milk
Allocation concealment
(selection bias)
Unclear risk Report states that "sealed envelopes" were used, but it is unclear whether
these were sequentially numbered and opaque
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk It is not reported whether personnel were blinded (participant blinding irrele-
vant in this context)
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk It is not reported whether outcome assessors were blinded
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Four infants (2 in intervention group 1, and 2 in intervention group 2) did not
complete the study because of feed intolerance. Results of growth outcomes
for these infants are not presented
Gross 1987 (2)  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 163 VLBW infants
Eligibility criteria: major congenital malformation, necrotising enterocolitis stage 2 or 3, not reaching
full volume feeds by day 21 of life
Setting: Department of Neonatology, Christian Medical College Vellore Tamil Nadu, India
Interventions Intervention 1 (N = 82): maternal milk mixed with infant formula powder (Simyl LBW, FDC Ltd, India) to
achieve 2 g protein and 88 kcal per 100 mL
Control (N = 81): human milk with no supplementation
Fortification with the powdered formula was continued until infant weight = 1800 g
Outcomes • Feed intolerance
• Necrotising enterocolitis
• Rate of weight and length gain and head circumference growth
• Duration of hospital stay
Notes All participants received multi-vitamin, calcium, and iron supplements
Study was supported by institutional research grant from Christian Medical College, Vellore
Risk of bias
Gupta 2018 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk "Statistician-generated" sequence
Allocation concealment
(selection bias)
Low risk Serially numbered, opaque envelopes
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Unblinded
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Unblinded
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Complete cohort analysis (by intention-to-treat)
Gupta 2018  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 275 preterm infants with birth weight < 1850 g
Eligibility criteria: no major congenital abnormalities, resident in UK, mother agreed to provide breast
milk
Setting: 2 centres in Cambridge and Norwich, UK
Interventions Intervention (N = 137): maternal milk supplemented with (per 100 mL) 0.7 g protein (bovine), 2.73 g
carbohydrate, 0.05 g fat, 90 mg calcium, and 45 mg phosphate, as well as electrolytes (Enfamil, Mead
Johnson)
Control (N = 138): maternal milk supplemented with 15 mg/100 mL phosphate
Enteral intake 180 mL/kg/d
Intervention ceased at discharge, or when weight reached 2000 g
All infants received vitamins (including vitamin D 260 IU/100 mL)
Infants whose mothers could not provide sufficient milk were supplemented with a preterm formula
and were not excluded from the analysis
Outcomes • In-hospital growth rates
• Growth to 9 and 18 months
• Neurodevelopmental outcomes at 9 and 18 months
• Serum indices of bone metabolism
• Necrotising enterocolitis
Notes Funded by Mead Johnson
Risk of bias
Bias Authors' judgement Support for judgement
Lucas 1996 
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Random sequence genera-
tion (selection bias)
Low risk Use of permuted blocks of randomised length
Allocation concealment
(selection bias)
Low risk Use of sealed opaque envelopes
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Unblinded
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Unblinded (except for assessment of neurodevelopmental outcomes)
Incomplete outcome data
(attrition bias)
All outcomes
Low risk No details of infants lost to follow-up are reported. Lack of attrition bias is as-
sumed
Lucas 1996  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 39 infants of birth weight between 1000 and 1500 g
Eligibility criteria: birth weight appropriate for gestational age, no ventilatory assistance after 7 days,
no supplemental oxygen after 10 days, fewer than 3 days of diuretic therapy, enteral feeding by 14 days
after birth
Setting: Miller Children's Hospital of Long Beach, California, USA
Interventions Intervention (N = 20): mother's own milk plus fortifier (to provide supplemental 0.7 g protein, 2.7 g car-
bohydrate, "trace" fat, 60 mg calcium, and 33 mg phosphate per 100 mL of breast milk)
Control (N = 19): mother's own milk
Formula and human milk were diluted initially and the fortifier was added gradually to milk for infants
in the intervention group to reach target calorific density over 7 days (approximately) in all groups. Milk
was generally provided by intermittent bolus gavage until nipple feedings were tolerated. Infants re-
ceived standard infant formula if their mother's milk was unavailable for "an occasional feeding" (up to
a maximum of 10% of feedings per week)
Outcomes • Growth rates (weight, length, head circumference)
• Feeding intolerance and necrotising enterocolitis
• Biochemical status
• Bone mineral content
Notes Intervention ceased at discharge, or when weight reached 1800 g
Risk of bias
Bias Authors' judgement Support for judgement
Modanlou 1986 
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Random sequence genera-
tion (selection bias)
Unclear risk Report states that infants were "randomly assigned", but method of sequence
generation is not described
Allocation concealment
(selection bias)
Unclear risk Report states that sealed envelopes were used. It is not reported whether
these were sequentially numbered and opaque
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Unblinded
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Unblinded
Incomplete outcome data
(attrition bias)
All outcomes
High risk 19 infants leT the study after randomisation because of "insufficient mater-
nal milk supply", and another 2 infants were withdrawn because of suspected
NEC. Outcome data for inclusion in intention-to-treat analyses were not avail-
able for these infants
Modanlou 1986  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 166 VLBW infants (and gestational age < 35 weeks at birth)
Eligibility criteria: feed volume of 150 mL/kg/d, feeds consisting of at least 80% breast milk, no congeni-
tal malformations nor gastrointestinal abnormalities
Setting: PGIMER, Chandigarh, India
Interventions Intervention (N = 85): breast milk fortified with Lactodex Human Milk Fortifier (2 g sachet per 50 mL of
milk: 0.2 g protein, 1.2 g carbohydrate, and 6.5 kcal energy)
Control (N = 81): breast milk with added vitamins and minerals
Outcomes • Growth rates (weight, length, head circumference)
• Biochemical parameters
• Length of hospital stay
• Feeding intolerance and necrotising enterocolitis
Notes Fortification was stopped once babies reached a weight of 2000 g or were fully breastfed
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table
Allocation concealment
(selection bias)
Unclear risk Details not reported
Mukhopadhyay 2007 
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Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk It is not reported whether personnel were blinded (participant blinding irrele-
vant in this context)
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk It is not reported whether outcome assessors were blinded
Incomplete outcome data
(attrition bias)
All outcomes
Low risk No details of infants lost to follow-up are reported. Lack of attrition bias is as-
sumed
Mukhopadhyay 2007  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 23 VLBW infants receiving enteral feeds of at least 150 mL/kg/d
Eligibility criteria: no fluid restriction, no diuretics, no postnatal systemic steroid use, no significant
congenital abnormality
Setting: neonatal intensive care unit, King's College Hospital, London, UK
Interventions Intervention (N = 13): maternal (or pasteurised pooled donor milk) supplemented (per 100 mL) with 0.7
g protein, 2.0 g carbohydrate, 30 mg calcium, 40 mg phosphorus, trace minerals, and vitamins
Control (N = 10): unsupplemented maternal or donor milk
Intervention ceased when infants no longer required nasogastric feeds
Outcomes • In-hospital growth parameters
• Indices of bone metabolism
Notes Intervention ceased when infants no longer required nasogastric feeds
One infant whose mother declined fortifier was included in results of non-fortified infants, and 1 baby
whose mother preferred the addition of fortifier was included in results of the intervention group
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Report states that infants were "randomised", but method of sequence gener-
ation is not described
Allocation concealment
(selection bias)
Low risk Sealed opaque envelopes
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Unblinded
Blinding of outcome as-
sessment (detection bias)
High risk Unblinded
Nicholl 1999 
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All outcomes
Incomplete outcome data
(attrition bias)
All outcomes
Low risk No details of infants lost to follow-up are reported. Lack of attrition bias is as-
sumed
Nicholl 1999  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 100 consecutive infants weighing between 1000 and 1500 g at birth
Eligibility criteria: no major congenital abnormalities or metabolic disturbances, no requirement for
ventilation at the point of entry into the study (day 4 after birth), free from serious infection, receiving
at least 45 mL/kg/d of gavage feedings (expressed breast milk) at the beginning of the study
Setting: Baragwanath Hospital, Bertsham, South Africa
Interventions Intervention (N = 53): mother's own milk supplemented with (per 100 mL) 0.05 g protein, 1.1 g carbo-
hydrate, 0.26 g fat, 72.3 mg calcium, and 34 mg phosphate, along with electrolytes and vitamins (HMF,
Ross Laboratories)
Control (N = 47): mother's own milk
Feeds were titrated as tolerated up to 200 mL/kg/d. Feeds were delivered by nasogastric tube until in-
fants weighed 1600 g. At this point, bottle feeding was introduced gradually. Infants were removed
from the study if their mother could not supply sufficient breast milk
Outcomes • Weight gain
• Serum calcium, phosphorus, alkaline phosphatase, and albumin levels
• Bone mineral homeostasis
• Necrotising enterocolitis (data obtained from trial investigators)
Notes 41 infants leT the study after randomisation for various reasons (insufficient maternal milk supply,
death, reduced enteral intake for > 72 hours, incomplete data). Data for these infants were not included
in intention-to-treat analyses of growth outcomes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Report states that infants were "randomly assigned", but method of sequence
generation is not described
Allocation concealment
(selection bias)
Unclear risk Details of allocation concealment not reported
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk It is not reported whether personnel were blinded (participant blinding irrele-
vant in this context)
Blinding of outcome as-
sessment (detection bias)
Unclear risk It is not reported whether outcome assessors were blinded
Pettifor 1989 
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All outcomes
Incomplete outcome data
(attrition bias)
All outcomes
High risk 41 (of 100) infants leT the study after randomisation for various reasons (insuf-
ficient maternal milk supply, death, reduced enteral intake for > 72 hours, in-
complete data). These infants were not included in intention-to-treat analyses
of growth outcomes
Pettifor 1989  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 34 VLBW infants
Eligibility criteria: birth weight appropriate for gestational age, tolerance of complete enteral feeding
(170 mL/kg/d), no obvious disease or major malformations, no supplemental oxygen therapy
Setting: 2 neonatal units in Lund and Malmö, Sweden
Interventions Intervention (N = 7): maternal or donor milk supplemented with (per 100 mL) 1.0 g human milk protein
and 1.0 g human milk fat
Control 1 (N = 7): maternal or donor milk with no fortification
Feeds of 170 mL/kg/d were given throughout the study. When mother's own milk was insufficient, ma-
ture human milk from a milk bank was used. All infants, regardless of group allocation, received enter-
al supplementation with vitamin E, folic acid, a multi-vitamin preparation, and additional vitamin D.
They also received one-oH administration of calcium and phosphate, and from 4 weeks of age, elemen-
tal iron was given
Outcomes • Growth parameters
Notes Six infants leT the study after randomisation for various reasons (apnoea, intolerance to the fixed feed
volume, need for intravenous therapy). These infants were not included in intention-to-treat analyses
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Report states that infants were "randomly assigned", but method of sequence
generation is not described
Allocation concealment
(selection bias)
Unclear risk Report states that "closed envelopes" were used, but it is not specified
whether these were sequentially numbered, opaque, and sealed
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk Described as "double-blind", but it is not specified who was blinded
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Described as "double-blind", but it is not specified who was blinded
Incomplete outcome data
(attrition bias)
High risk Several (up to 6, but exact number unclear) infants were excluded from the
study after randomisation; intention-to-treat analyses were not reported
Polberger 1989 
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All outcomes
Polberger 1989  (Continued)
 
 
Study characteristics
Methods Randomised controlled trial
Participants 20 preterm infants with birth weight between 1110 and 2000 g
Eligibility criteria: none reported
Setting: Pediatric Hospital "V. Buzzi", Milano, Italy
Interventions Intervention (N = 10): human milk fortified with FM85 Nestlè (including energy and protein)
Control 1 (N =10): human milk with no fortification
All infants received supplemental vitamin D
Outcomes • Growth parameters
• Metabolic parameters
• Measures of bone mineralisation
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Report states that infants were "randomised", but method of sequence gener-
ation is not described
Allocation concealment
(selection bias)
Unclear risk Details of allocation concealment are not reported
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Unclear risk It is not reported whether personnel were blinded (participant blinding irrele-
vant in this context)
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk It is not reported whether outcome assessors were blinded
Incomplete outcome data
(attrition bias)
All outcomes
Low risk No details of infants lost to follow-up are reported. Lack of attrition bias is as-
sumed
Porcelli 1992 
 
 
Study characteristics
Methods Randomised controlled trial
Wauben 1998 
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Participants 31 preterm infants of birth weight < 1800 g
Eligibility criteria: older than 1 week of age (birth weight appropriate for gestational age), consumption
of full oral feeds (enteral intake 160 mL/kg/d) for longer than 5 days, stable weight gain greater than 10
g/kg/d, no severe congenital malformations/chromosomal abnormalities, no gastrointestinal disease
Setting: Neonatal Units of the Children's Hospitals of the Hamilton Health Sciences Corporation and St
Joseph's Hospitals, Hamilton, Ontario, Canada
Interventions Intervention (N = 15): maternal milk fortified with (per 100 mL) 0.37 g human milk protein, 3.47 g carbo-
hydrate, 61 mg calcium, 44 mg phosphorus, electrolytes and other minerals, and vitamins (including vi-
tamin D 472 IU/d) (Wyeth-Ayerst, Toronto, Ontario, Canada) (fortification commenced when maternal
milk contributed > 80% of infant's enteral intake)
Control (N = 16): maternal milk supplemented with calcium glycerophosphate
Outcomes • Short-term growth
• Biochemical indices of bone metabolism
• Bone mineral content
Notes Supplementation in both groups was increased gradually until a target amount was reached. Interven-
tion ceased at discharge or at 38 weeks' postmenstrual age, whichever occurred later
Infants in the control arm were significantly lighter at birth and were significantly lighter and shorter at
study entry than infants in the group receiving HMF
Nutrient intakes were measured: mean fluid intakes were significantly greater in the control group (177
vs 164 mL/kg/d)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Random numbers table
Allocation concealment
(selection bias)
Unclear risk Details of allocation concealment are not reported
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Unblinded
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Unblinded
Incomplete outcome data
(attrition bias)
All outcomes
High risk Six infants (3 in each group) were excluded from the study after randomisa-
tion. Details are reported, and no bias was apparent between groups. Inten-
tion-to-treat analyses of growth outcomes data are not reported
Wauben 1998  (Continued)
 
 
Study characteristics
Methods Quasi-randomised controlled trial
Zuckerman 1994 
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Participants 56 infants with birth weight < 1200 g, older than 2 weeks of age
Eligibility criteria: no congenital abnormalities, infections, nor disorders causing bone disease
Setting: Baragwanath Hospital, Bertsham, South Africa
Interventions Intervention (N = 29): maternal milk mixed in equal proportions with preterm infant formula (Alprem,
Nestle) to yield supplements (per 100 mL) of fat, carbohydrate, and calcium 14.5 mg; phosphate 7 mg;
and protein 0.6 g
Control (N = 27): unsupplemented human milk
Outcomes • In-hospital growth rates
• Serum indices of bone metabolism
• Radiographic changes in metabolic bone disease
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Infants were assigned to the 2 groups according to their hospital number (odd
or even)
Allocation concealment
(selection bias)
High risk Infants were assigned to the 2 groups according to their hospital number (odd
or even)
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Unblinded
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Unblinded (radiographers are reported to have been blinded)
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Three infants in the control group were excluded because of incorrect feeding
Zuckerman 1994  (Continued)
ALP: alkaline phosphatase.
DEXA: dual-energy X-ray absorptiometry.
NEC: necrotising enterocolitis.
NICU: neonatal intensive care unit.
VLBW: very low birth weight.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Abrams 2014 Comparison of human milk-based vs cow's milk-based protein fortification
Arco 2002 Not an RCT
Arslanoglu 2009 Comparison of different fortification regimens, with no control group receiving unfortified milk
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Study Reason for exclusion
Atchley 2019 Fortification with protein only; comparison of diets with different energy:protein ratios
Biasini 2017 Not an RCT
Carey 1987 Fortification with protein only; no fortification with energy
Chan 2000 Comparison of different fortifiers, with no control group receiving unfortified milk
Greer 1988 Fortification with protein only; no fortification with energy
Hair 2014 Control group received fortified milk
Kashyap 1990 Fortification with protein only; no fortification with energy
Kim 2015 Comparison of different fortifiers (liquid vs powder), with no control group receiving unfortified
milk
Miura 2009 Comparison of different fortifiers (MCT vs non-MCT enriched), with no control group receiving un-
fortified milk
Ramaswamy 2019 Not a randomised controlled trial (commentary on Gupta 2018)
Reali 2010 Literature review
Tarcan 2004 Not a randomised controlled trial
MCT: medium-chain triglyceride.
RCT: randomised controlled trial.
 
Characteristics of studies awaiting classification [ordered by study ID]
 
Methods Randomised controlled trial
Participants Infants born before 33 weeks' gestation, with blood urea level < 2.5 mmol/L
Interventions "Breast milk fortifier" containing long-chain unsaturated fatty acids
Outcomes Term body composition (adipose and lean tissue content)
Notes Unpublished (brief abstract only) - further information sought from authors in October 2019 (not
available)
Uthaya 2007 
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name PREterM FOrmula Or Donor Breast Milk for Premature Babies (PREMFOOD)
Methods Open, 3-arm randomised controlled feasibility trial
Mills 2015 
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Participants Neonates at < 30 weeks' gestation; babies with conditions that preclude enteral feeding or are im-
mediately life-limiting are ineligible
Interventions Participants will be randomised to receive fortified donor breast milk (DBM), unfortified DBM, or
preterm formula to make up any shortfall in maternal breast milk until 35 weeks' postmenstrual
age, with a sample size of 22 in each group
Outcomes Primary outcome measure: total body adiposity (measured as close as possible to the baby's due
date, at an average age of 10 weeks (range 8 to 15 weeks))
Starting date 2015
Contact information Prof. Neena Modi, Section of Neonatal Medicine, Imperial College London, London, UK; Depart-
ment of Neonatal Medicine, Chelsea and Westminster Hospital, London, UK
Notes Feasibility trial
Mills 2015  (Continued)
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Fortified breast milk versus unfortified breast milk
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.1 Weight gain (g/kg/d) 14   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1.1 All trials 14 951 Mean Difference (IV, Fixed, 95% CI) 1.76 [1.30, 2.22]
1.1.2 Trials recruiting only very preterm
or VLBW infants
8 505 Mean Difference (IV, Fixed, 95% CI) 2.18 [1.54, 2.81]
1.1.3 Trials conducted in low- or mid-
dle-income countries
6 530 Mean Difference (IV, Fixed, 95% CI) 1.73 [1.10, 2.35]
1.1.4 Trials using preterm formula pow-
der as fortifier
3 224 Mean Difference (IV, Fixed, 95% CI) 2.20 [1.36, 3.04]
1.2 Length gain (cm/week) 10   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.2.1 All trials 10 741 Mean Difference (IV, Fixed, 95% CI) 0.11 [0.08, 0.15]
1.2.2 Trials recruiting only very preterm
or VLBW infants
5 375 Mean Difference (IV, Fixed, 95% CI) 0.16 [0.11, 0.20]
1.2.3 Trials conducted in low- or mid-
dle-income countries
3 343 Mean Difference (IV, Fixed, 95% CI) 0.14 [0.09, 0.19]
1.2.4 Trials using preterm formula pow-
der as fortifier
2 174 Mean Difference (IV, Fixed, 95% CI) 0.07 [0.01, 0.14]
1.3 Head growth (cm/week) 11   Mean Difference (IV, Fixed, 95% CI) Subtotals only
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.3.1 All trials 11 821 Mean Difference (IV, Fixed, 95% CI) 0.06 [0.03, 0.08]
1.3.2 Trials recruiting only very preterm
or VLBW infants
5 375 Mean Difference (IV, Fixed, 95% CI) 0.07 [0.03, 0.11]
1.3.3 Trials conducted in low- or mid-
dle-income countries
4 423 Mean Difference (IV, Fixed, 95% CI) 0.04 [0.01, 0.08]
1.3.4 Trials using preterm formula pow-
der as fortifier
2 174 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.00, 0.11]
1.4 Weight at 12 to 18 months (kg) 2 270 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.31, 0.25]
1.5 Length at 12 to 18 months (cm) 2 270 Mean Difference (IV, Fixed, 95% CI) -0.19 [-0.98, 0.60]
1.6 Head circumference at 12 to 18
months (cm)
2 270 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.37, 0.18]
1.7 Mental development index at 18
months
1 245 Mean Difference (IV, Fixed, 95% CI) 2.20 [-3.35, 7.75]
1.8 Psychomotor development index at
18 months
1 245 Mean Difference (IV, Fixed, 95% CI) 2.40 [-1.90, 6.70]
1.9 Length of hospital stay (weeks) 6   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.9.1 All trials 6 526 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.35, 0.21]
1.9.2 Trials recruiting only very preterm
or VLBW infants
3 236 Mean Difference (IV, Fixed, 95% CI) -0.48 [-0.89, -0.08]
1.9.3 Trials conducted in low- or mid-
dle-income countries
4 316 Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.55, 0.09]
1.9.4 Trials using preterm formula pow-
der as fortifier
3 251 Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.85, -0.05]
1.10 Feed intolerance 7   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.10.1 All trials 7 453 Risk Ratio (M-H, Fixed, 95% CI) 1.05 [0.65, 1.67]
1.10.2 Trials recruiting only very preterm
or VLBW infants
4 372 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.55, 1.45]
1.10.3 Trials conducted in low- or mid-
dle-income countries
3 355 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.54, 1.47]
1.10.4 Trials using preterm formula pow-
der as fortifier
3 228 Risk Ratio (M-H, Fixed, 95% CI) 2.63 [0.79, 8.71]
1.11 Necrotising enterocolitis 13   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.11.1 All trials 13 1110 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.72, 2.63]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.11.2 Trials recruiting only very preterm
or VLBW infants
9 701 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.55, 2.99]
1.11.3 Trials conducted in low- or mid-
dle-income countries
6 552 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.36, 3.38]
1.11.4 Trials using preterm formula pow-
der as fortifier
2 201 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.21, 10.76]
1.12 Serum ALP (IU/L): restricted to trials
without mineral supplementation of the
control group
6   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.12.1 All trials 6 363 Mean Difference (IV, Fixed, 95% CI) -141.93 [-203.93,
-79.92]
1.12.2 Trials recruiting only very preterm
or VLBW infants
4 265 Mean Difference (IV, Fixed, 95% CI) -132.03 [-198.09,
-65.98]
1.12.3 Trials conducted in low- or mid-
dle-income countries
4 309 Mean Difference (IV, Fixed, 95% CI) -119.66 [-185.54,
-53.78]
1.12.4 Trials using preterm formula pow-
der as fortifier
1 33 Mean Difference (IV, Fixed, 95% CI) -261.00 [-539.14,
17.14]
1.13 Bone mineral content (mg/cm): re-
stricted to trials without mineral supple-
mentation of the control group
1 59 Mean Difference (IV, Fixed, 95% CI) 12.00 [6.28, 17.72]
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Analysis 1.1.   Comparison 1: Fortified breast milk versus unfortified breast milk, Outcome 1: Weight gain (g/kg/d)
Study or Subgroup
1.1.1 All trials
Modanlou 1986
Gross 1987 (1)
Gross 1987 (2)
Polberger 1989
Pettifor 1989
Porcelli 1992
Lucas 1996
Wauben 1998
Nicholl 1999
Mukhopadhyay 2007
Einloft 2015
El Sakka 2016
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 37.16, df = 13 (P = 0.0004); I² = 65%
Test for overall effect: Z = 7.52 (P < 0.00001)
1.1.2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986
Polberger 1989
Pettifor 1989
Nicholl 1999
Mukhopadhyay 2007
Einloft 2015
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 23.18, df = 7 (P = 0.002); I² = 70%
Test for overall effect: Z = 6.67 (P < 0.00001)
1.1.3 Trials conducted in low- or middle-income countries
Pettifor 1989
Mukhopadhyay 2007
Einloft 2015
El Sakka 2016
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 6.44, df = 5 (P = 0.27); I² = 22%
Test for overall effect: Z = 5.40 (P < 0.00001)
1.1.4 Trials using preterm formula powder as fortifier
Gross 1987 (2)
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 2.38, df = 2 (P = 0.30); I² = 16%
Test for overall effect: Z = 5.11 (P < 0.00001)
Test for subgroup differences: Chi² = 1.85, df = 3 (P = 0.60), I² = 0%
Fortified
Mean
26.7
19.9
21.5
20.4
16.7
11.4
15.6
16.6
15.1
15.1
19.2
16.8
18
9.4
26.7
20.4
16.7
15.1
15.1
19.2
16.8
18
16.7
15.1
19.2
16.8
18
9.4
21.5
16.8
18
SD
3.4
2.5
3.5
2.8
5
2.7
4.7
1.6
3.3
4
4.3
5.5
2.9
2.2
3.4
2.8
5
3.3
4
4.3
5.5
2.9
5
4
4.3
5.5
2.9
2.2
3.5
5.5
2.9
Total
8
10
17
7
29
10
137
12
13
82
19
25
75
40
484
8
7
29
13
82
19
25
75
258
29
82
19
25
75
40
270
17
25
75
117
Unfortified
Mean
19.4
17.7
17.5
15.3
16.8
12
15
14.2
13.2
12.9
19.9
13.8
16.1
7.9
19.4
15.3
16.8
13.2
12.9
19.9
13.8
16.1
16.8
12.9
19.9
13.8
16.1
7.9
17.5
13.8
16.1
SD
2.7
4.4
3.3
3.2
6.4
3
3.5
2
6.4
4
3.7
4.7
2.9
4.8
2.7
3.2
6.4
6.4
4
3.7
4.7
2.9
6.4
4
3.7
4.7
2.9
4.8
3.3
4.7
2.9
Total
10
10
9
7
28
10
138
13
10
75
19
25
73
40
467
10
7
28
10
75
19
25
73
247
28
75
19
25
73
40
260
9
25
73
107
Weight
2.5%
2.1%
2.8%
2.1%
2.4%
3.4%
21.9%
10.5%
1.1%
13.4%
3.2%
2.6%
24.1%
7.9%
100.0%
4.9%
4.1%
4.6%
2.2%
26.1%
6.3%
5.1%
46.8%
100.0%
4.4%
25.0%
6.0%
4.9%
45.0%
14.7%
100.0%
9.6%
8.9%
81.5%
100.0%
Mean Difference
IV, Fixed, 95% CI
7.30 [4.41 , 10.19]
2.20 [-0.94 , 5.34]
4.00 [1.28 , 6.72]
5.10 [1.95 , 8.25]
-0.10 [-3.09 , 2.89]
-0.60 [-3.10 , 1.90]
0.60 [-0.38 , 1.58]
2.40 [0.99 , 3.81]
1.90 [-2.45 , 6.25]
2.20 [0.95 , 3.45]
-0.70 [-3.25 , 1.85]
3.00 [0.16 , 5.84]
1.90 [0.97 , 2.83]
1.50 [-0.14 , 3.14]
1.76 [1.30 , 2.22]
7.30 [4.41 , 10.19]
5.10 [1.95 , 8.25]
-0.10 [-3.09 , 2.89]
1.90 [-2.45 , 6.25]
2.20 [0.95 , 3.45]
-0.70 [-3.25 , 1.85]
3.00 [0.16 , 5.84]
1.90 [0.97 , 2.83]
2.18 [1.54 , 2.81]
-0.10 [-3.09 , 2.89]
2.20 [0.95 , 3.45]
-0.70 [-3.25 , 1.85]
3.00 [0.16 , 5.84]
1.90 [0.97 , 2.83]
1.50 [-0.14 , 3.14]
1.73 [1.10 , 2.35]
4.00 [1.28 , 6.72]
3.00 [0.16 , 5.84]
1.90 [0.97 , 2.83]
2.20 [1.36 , 3.04]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours control Favours fortified
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Analysis 1.2.   Comparison 1: Fortified breast milk versus unfortified breast milk, Outcome 2: Length gain (cm/week)
Study or Subgroup
1.2.1 All trials
Modanlou 1986
Gross 1987 (2)
Gross 1987 (1)
Polberger 1989
Porcelli 1992
Lucas 1996
Wauben 1998
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 29.00, df = 9 (P = 0.0006); I² = 69%
Test for overall effect: Z = 5.67 (P < 0.00001)
1.2.2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986
Polberger 1989
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 14.21, df = 4 (P = 0.007); I² = 72%
Test for overall effect: Z = 6.20 (P < 0.00001)
1.2.3 Trials conducted in low- or middle-income countries
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 8.14, df = 2 (P = 0.02); I² = 75%
Test for overall effect: Z = 5.20 (P < 0.00001)
1.2.4 Trials using preterm formula powder as fortifier
Gross 1987 (2)
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 0.14, df = 1 (P = 0.71); I² = 0%
Test for overall effect: Z = 2.28 (P = 0.02)
Test for subgroup differences: Chi² = 4.41, df = 3 (P = 0.22), I² = 32.0%
Fortified
Mean
0.99
0.84
0.89
1.2
0.6
0.93
1.1
1.04
1.2
1.04
0.99
1.2
1.04
1.2
1.04
1.04
1.2
1.04
0.84
1.04
SD
0.4
0.25
0.19
0.17
0.2
0.47
0.2
0.3
0.5
0.21
0.4
0.17
0.3
0.5
0.21
0.3
0.5
0.21
0.25
0.21
Total
8
17
10
7
10
137
12
82
19
75
377
8
7
82
19
75
191
82
19
75
176
17
75
92
Unfortified
Mean
0.81
0.79
0.81
0.83
0.7
0.96
0.9
0.86
0.8
0.96
0.81
0.83
0.86
0.8
0.96
0.86
0.8
0.96
0.79
0.96
SD
0.44
0.12
0.22
0.17
0.3
0.47
0.2
0.2
0.2
0.23
0.44
0.17
0.2
0.2
0.23
0.2
0.2
0.23
0.12
0.23
Total
10
9
10
7
10
138
13
75
19
73
364
10
7
75
19
73
184
75
19
73
167
9
73
82
Weight
1.0%
7.8%
4.9%
5.0%
3.2%
12.8%
6.4%
25.1%
2.7%
31.2%
100.0%
1.6%
7.6%
38.6%
4.1%
48.0%
100.0%
42.6%
4.5%
52.9%
100.0%
19.9%
80.1%
100.0%
Mean Difference
IV, Fixed, 95% CI
0.18 [-0.21 , 0.57]
0.05 [-0.09 , 0.19]
0.08 [-0.10 , 0.26]
0.37 [0.19 , 0.55]
-0.10 [-0.32 , 0.12]
-0.03 [-0.14 , 0.08]
0.20 [0.04 , 0.36]
0.18 [0.10 , 0.26]
0.40 [0.16 , 0.64]
0.08 [0.01 , 0.15]
0.11 [0.08 , 0.15]
0.18 [-0.21 , 0.57]
0.37 [0.19 , 0.55]
0.18 [0.10 , 0.26]
0.40 [0.16 , 0.64]
0.08 [0.01 , 0.15]
0.16 [0.11 , 0.20]
0.18 [0.10 , 0.26]
0.40 [0.16 , 0.64]
0.08 [0.01 , 0.15]
0.14 [0.09 , 0.19]
0.05 [-0.09 , 0.19]
0.08 [0.01 , 0.15]
0.07 [0.01 , 0.14]
Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours control Favours fortified
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Analysis 1.3.   Comparison 1: Fortified breast milk versus
unfortified breast milk, Outcome 3: Head growth (cm/week)
Study or Subgroup
1.3.1 All trials
Modanlou 1986
Gross 1987 (2)
Gross 1987 (1)
Polberger 1989
Porcelli 1992
Lucas 1996
Wauben 1998
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 17.26, df = 10 (P = 0.07); I² = 42%
Test for overall effect: Z = 4.01 (P < 0.0001)
1.3.2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986
Polberger 1989
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 13.08, df = 4 (P = 0.01); I² = 69%
Test for overall effect: Z = 3.66 (P = 0.0003)
1.3.3 Trials conducted in low- or middle-income countries
Mukhopadhyay 2007
Einloft 2015
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 6.45, df = 3 (P = 0.09); I² = 53%
Test for overall effect: Z = 2.55 (P = 0.01)
1.3.4 Trials using preterm formula powder as fortifier
Gross 1987 (2)
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 1.08, df = 1 (P = 0.30); I² = 8%
Test for overall effect: Z = 1.92 (P = 0.06)
Test for subgroup differences: Chi² = 1.25, df = 3 (P = 0.74), I² = 0%
Fortified
Mean
1.09
0.84
0.92
1.11
0.7
1.01
1
0.83
0.91
0.97
0.56
1.09
1.11
0.83
0.91
0.97
0.83
0.91
0.97
0.56
0.84
0.97
SD
0.07
0.21
0.09
0.13
0.3
0.47
0.1
0.2
0.21
0.19
0.1
0.07
0.13
0.2
0.21
0.19
0.2
0.21
0.19
0.1
0.21
0.19
Total
8
17
10
7
10
137
12
82
19
75
40
417
8
7
82
19
75
191
82
19
75
40
216
17
75
92
Unfortified
Mean
0.82
0.84
0.83
0.94
0.7
0.95
0.9
0.75
0.98
0.9
0.54
0.82
0.94
0.75
0.98
0.9
0.75
0.98
0.9
0.54
0.84
0.9
SD
0.24
0.09
0.16
0.25
0.2
0.35
0.2
0.2
0.14
0.2
0.16
0.24
0.25
0.2
0.14
0.2
0.2
0.14
0.2
0.16
0.09
0.2
Total
10
9
10
7
10
138
13
75
19
73
40
404
10
7
75
19
73
184
75
19
73
40
207
9
73
82
Weight
3.2%
5.8%
6.0%
1.8%
1.6%
8.1%
5.2%
19.9%
6.0%
19.7%
22.8%
100.0%
6.3%
3.5%
39.3%
12.0%
39.0%
100.0%
29.0%
8.8%
28.8%
33.3%
100.0%
22.8%
77.2%
100.0%
Mean Difference
IV, Fixed, 95% CI
0.27 [0.11 , 0.43]
0.00 [-0.12 , 0.12]
0.09 [-0.02 , 0.20]
0.17 [-0.04 , 0.38]
0.00 [-0.22 , 0.22]
0.06 [-0.04 , 0.16]
0.10 [-0.02 , 0.22]
0.08 [0.02 , 0.14]
-0.07 [-0.18 , 0.04]
0.07 [0.01 , 0.13]
0.02 [-0.04 , 0.08]
0.06 [0.03 , 0.08]
0.27 [0.11 , 0.43]
0.17 [-0.04 , 0.38]
0.08 [0.02 , 0.14]
-0.07 [-0.18 , 0.04]
0.07 [0.01 , 0.13]
0.07 [0.03 , 0.11]
0.08 [0.02 , 0.14]
-0.07 [-0.18 , 0.04]
0.07 [0.01 , 0.13]
0.02 [-0.04 , 0.08]
0.04 [0.01 , 0.08]
0.00 [-0.12 , 0.12]
0.07 [0.01 , 0.13]
0.05 [-0.00 , 0.11]
Mean Difference
IV, Fixed, 95% CI
-0.2 -0.1 0 0.1 0.2
Favours control Favours fortified
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Analysis 1.4.   Comparison 1: Fortified breast milk versus
unfortified breast milk, Outcome 4: Weight at 12 to 18 months (kg)
Study or Subgroup
Lucas 1996
Wauben 1998
Total (95% CI)
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.92); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.81)
Test for subgroup differences: Not applicable
Fortified
Mean
10.05
9
SD
1.34
0.9
Total
125
12
137
Unfortified
Mean
10.09
9
SD
1.1
0.9
Total
120
13
133
Weight
84.2%
15.8%
100.0%
Mean Difference
IV, Fixed, 95% CI
-0.04 [-0.35 , 0.27]
0.00 [-0.71 , 0.71]
-0.03 [-0.31 , 0.25]
Mean Difference
IV, Fixed, 95% CI
-0.5 -0.25 0 0.25 0.5
Favours control Favours fortified
 
 
Analysis 1.5.   Comparison 1: Fortified breast milk versus
unfortified breast milk, Outcome 5: Length at 12 to 18 months (cm)
Study or Subgroup
Lucas 1996
Wauben 1998
Total (95% CI)
Heterogeneity: Chi² = 0.45, df = 1 (P = 0.50); I² = 0%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
Fortified
Mean
80
74.9
SD
3.35
3.7
Total
125
12
137
Unfortified
Mean
80.1
75.9
SD
3.29
2.5
Total
120
13
133
Weight
90.0%
10.0%
100.0%
Mean Difference
IV, Fixed, 95% CI
-0.10 [-0.93 , 0.73]
-1.00 [-3.50 , 1.50]
-0.19 [-0.98 , 0.60]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours control Favours fortified
 
 
Analysis 1.6.   Comparison 1: Fortified breast milk versus unfortified
breast milk, Outcome 6: Head circumference at 12 to 18 months (cm)
Study or Subgroup
Lucas 1996
Wauben 1998
Total (95% CI)
Heterogeneity: Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
Fortified
Mean
48
46.9
SD
1.12
3.9
Total
125
12
137
Unfortified
Mean
48.1
46.8
SD
1.1
1.3
Total
120
13
133
Weight
98.6%
1.4%
100.0%
Mean Difference
IV, Fixed, 95% CI
-0.10 [-0.38 , 0.18]
0.10 [-2.22 , 2.42]
-0.10 [-0.37 , 0.18]
Mean Difference
IV, Fixed, 95% CI
-2 -1 0 1 2
Favours control Favours fortified
 
 
Analysis 1.7.   Comparison 1: Fortified breast milk versus unfortified
breast milk, Outcome 7: Mental development index at 18 months
Study or Subgroup
Lucas 1996
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
Test for subgroup differences: Not applicable
Fortified
Mean
106
SD
22.4
Total
125
125
Unfortified
Mean
103.8
SD
21.9
Total
120
120
Weight
100.0%
100.0%
Mean Difference
IV, Fixed, 95% CI
2.20 [-3.35 , 7.75]
2.20 [-3.35 , 7.75]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours control Favours fortified
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Analysis 1.8.   Comparison 1: Fortified breast milk versus unfortified
breast milk, Outcome 8: Psychomotor development index at 18 months
Study or Subgroup
Lucas 1996
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.09 (P = 0.27)
Test for subgroup differences: Not applicable
Fortified
Mean
92.3
SD
17.9
Total
125
125
Unfortified
Mean
89.9
SD
16.4
Total
120
120
Weight
100.0%
100.0%
Mean Difference
IV, Fixed, 95% CI
2.40 [-1.90 , 6.70]
2.40 [-1.90 , 6.70]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours control Favours fortified
 
 
Analysis 1.9.   Comparison 1: Fortified breast milk versus
unfortified breast milk, Outcome 9: Length of hospital stay (weeks)
Study or Subgroup
1.9.1 All trials
Zuckerman 1994
Mukhopadhyay 2007
Einloft 2015
El Sakka 2016
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 12.35, df = 5 (P = 0.03); I² = 60%
Test for overall effect: Z = 0.49 (P = 0.62)
1.9.2 Trials recruiting only very preterm or VLBW infants
Einloft 2015
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 4.69, df = 2 (P = 0.10); I² = 57%
Test for overall effect: Z = 2.33 (P = 0.02)
1.9.3 Trials conducted in low- or middle-income countries
Einloft 2015
El Sakka 2016
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Heterogeneity: Chi² = 8.74, df = 3 (P = 0.03); I² = 66%
Test for overall effect: Z = 1.39 (P = 0.16)
1.9.4 Trials using preterm formula powder as fortifier
Zuckerman 1994
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Heterogeneity: Chi² = 5.16, df = 2 (P = 0.08); I² = 61%
Test for overall effect: Z = 2.23 (P = 0.03)
Test for subgroup differences: Chi² = 3.90, df = 3 (P = 0.27), I² = 23.1%
Fortified
Mean
7.86
4.56
5.2
3.2
5
2.2
5.2
3.2
5
5.2
3.2
5
2.2
7.86
3.2
5
SD
2
2.31
1.6
1.2
1.7
1.1
1.6
1.2
1.7
1.6
1.2
1.7
1.1
2
1.2
1.7
Total
29
82
19
25
75
40
270
19
25
75
119
19
25
75
40
159
29
25
75
129
Unfortified
Mean
7.43
4.2
4.7
4.1
5.4
2
4.7
4.1
5.4
4.7
4.1
5.4
2
7.43
4.1
5.4
SD
1.57
1.89
1.9
1.1
2
1.3
1.9
1.1
2
1.9
1.1
2
1.3
1.57
1.1
2
Total
24
75
19
25
73
40
256
19
25
73
117
19
25
73
40
157
24
25
73
122
Weight
8.3%
17.7%
6.2%
18.8%
21.4%
27.6%
100.0%
13.3%
40.6%
46.1%
100.0%
8.3%
25.5%
28.9%
37.3%
100.0%
17.1%
38.8%
44.1%
100.0%
Mean Difference
IV, Fixed, 95% CI
0.43 [-0.53 , 1.39]
0.36 [-0.30 , 1.02]
0.50 [-0.62 , 1.62]
-0.90 [-1.54 , -0.26]
-0.40 [-1.00 , 0.20]
0.20 [-0.33 , 0.73]
-0.07 [-0.35 , 0.21]
0.50 [-0.62 , 1.62]
-0.90 [-1.54 , -0.26]
-0.40 [-1.00 , 0.20]
-0.48 [-0.89 , -0.08]
0.50 [-0.62 , 1.62]
-0.90 [-1.54 , -0.26]
-0.40 [-1.00 , 0.20]
0.20 [-0.33 , 0.73]
-0.23 [-0.55 , 0.09]
0.43 [-0.53 , 1.39]
-0.90 [-1.54 , -0.26]
-0.40 [-1.00 , 0.20]
-0.45 [-0.85 , -0.05]
Mean Difference
IV, Fixed, 95% CI
-1 -0.5 0 0.5 1
Favours fortified Favours control
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Analysis 1.10.   Comparison 1: Fortified breast milk versus unfortified breast milk, Outcome 10: Feed intolerance
Study or Subgroup
1.10.1 All trials
Gross 1987 (2)
Gross 1987 (1)
Polberger 1989
Wauben 1998
Mukhopadhyay 2007
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 5.44, df = 5 (P = 0.36); I² = 8%
Test for overall effect: Z = 0.19 (P = 0.85)
1.10.2 Trials recruiting only very preterm or VLBW infants
Polberger 1989
Mukhopadhyay 2007
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 2.70, df = 3 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.46 (P = 0.65)
1.10.3 Trials conducted in low- or middle-income countries
Mukhopadhyay 2007
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 2.70, df = 2 (P = 0.26); I² = 26%
Test for overall effect: Z = 0.45 (P = 0.65)
1.10.4 Trials using preterm formula powder as fortifier
Gross 1987 (2)
El Sakka 2016
Gupta 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.23, df = 2 (P = 0.89); I² = 0%
Test for overall effect: Z = 1.58 (P = 0.11)
Test for subgroup differences: Chi² = 2.94, df = 3 (P = 0.40), I² = 0%
Fortified
Events
4
0
1
2
17
3
4
31
1
17
3
4
25
17
3
4
24
4
3
4
11
Total
21
10
9
15
82
25
75
237
9
82
25
75
191
82
25
75
182
21
25
75
121
Unfortified
Events
0
0
1
0
22
1
2
26
1
22
1
2
26
22
1
2
25
0
1
2
3
Total
9
10
8
16
75
25
73
216
8
75
25
73
181
75
25
73
173
9
25
73
107
Weight
2.4%
3.7%
1.7%
81.4%
3.5%
7.2%
100.0%
3.9%
84.9%
3.7%
7.5%
100.0%
88.4%
3.8%
7.8%
100.0%
18.5%
26.9%
54.6%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
4.09 [0.24 , 68.94]
Not estimable
0.89 [0.07 , 12.00]
5.31 [0.28 , 102.38]
0.71 [0.41 , 1.23]
3.00 [0.33 , 26.92]
1.95 [0.37 , 10.30]
1.05 [0.65 , 1.67]
0.89 [0.07 , 12.00]
0.71 [0.41 , 1.23]
3.00 [0.33 , 26.92]
1.95 [0.37 , 10.30]
0.89 [0.55 , 1.45]
0.71 [0.41 , 1.23]
3.00 [0.33 , 26.92]
1.95 [0.37 , 10.30]
0.89 [0.54 , 1.47]
4.09 [0.24 , 68.94]
3.00 [0.33 , 26.92]
1.95 [0.37 , 10.30]
2.63 [0.79 , 8.71]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours fortified Favours control
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Analysis 1.11.   Comparison 1: Fortified breast milk versus unfortified breast milk, Outcome 11: Necrotising
enterocolitis
Study or Subgroup
1.11.1 All trials
Faerk 2000
Modanlou 1986
Pettifor 1989
Polberger 1989
Porcelli 1992
Zuckerman 1994
Lucas 1996
Wauben 1998
Nicholl 1999
Bhat 2003
Mukhopadhyay 2007
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 5.35, df = 7 (P = 0.62); I² = 0%
Test for overall effect: Z = 0.95 (P = 0.34)
1.11.2 Trials recruiting only very preterm or VLBW infants
Faerk 2000
Modanlou 1986
Pettifor 1989
Polberger 1989
Porcelli 1992
Zuckerman 1994
Bhat 2003
Mukhopadhyay 2007
Gupta 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 2.70, df = 5 (P = 0.75); I² = 0%
Test for overall effect: Z = 0.58 (P = 0.57)
1.11.3 Trials conducted in low- or middle-income countries
Pettifor 1989
Porcelli 1992
Zuckerman 1994
Mukhopadhyay 2007
Gupta 2018
Adhisivam 2019
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 2.12, df = 3 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.16 (P = 0.87)
1.11.4 Trials using preterm formula powder as fortifier
Zuckerman 1994
Gupta 2018
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.35, df = 1 (P = 0.55); I² = 0%
Fortified
Events
1
2
3
0
0
1
8
0
0
3
0
1
1
20
1
2
3
0
0
1
3
0
1
11
3
0
1
0
1
1
6
1
1
2
Total
36
20
53
7
7
29
137
15
13
50
82
75
40
564
36
20
53
7
7
29
50
82
75
359
53
7
29
82
75
40
286
29
75
104
Unfortified
Events
1
0
1
0
0
1
3
0
0
5
0
0
3
14
1
0
1
0
0
1
5
0
0
8
1
0
1
0
0
3
5
1
0
1
Total
40
19
47
7
7
24
138
16
10
50
75
73
40
546
40
19
47
7
7
24
50
75
73
342
47
7
24
75
73
40
266
24
73
97
Weight
6.3%
3.4%
7.0%
7.2%
19.8%
33.1%
3.4%
19.9%
100.0%
10.4%
5.6%
11.6%
12.0%
54.8%
5.6%
100.0%
18.7%
19.3%
9.0%
53.0%
100.0%
68.4%
31.6%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
1.11 [0.07 , 17.12]
4.76 [0.24 , 93.19]
2.66 [0.29 , 24.71]
Not estimable
Not estimable
0.83 [0.05 , 12.54]
2.69 [0.73 , 9.91]
Not estimable
Not estimable
0.60 [0.15 , 2.38]
Not estimable
2.92 [0.12 , 70.56]
0.33 [0.04 , 3.07]
1.37 [0.72 , 2.63]
1.11 [0.07 , 17.12]
4.76 [0.24 , 93.19]
2.66 [0.29 , 24.71]
Not estimable
Not estimable
0.83 [0.05 , 12.54]
0.60 [0.15 , 2.38]
Not estimable
2.92 [0.12 , 70.56]
1.28 [0.55 , 2.99]
2.66 [0.29 , 24.71]
Not estimable
0.83 [0.05 , 12.54]
Not estimable
2.92 [0.12 , 70.56]
0.33 [0.04 , 3.07]
1.10 [0.36 , 3.38]
0.83 [0.05 , 12.54]
2.92 [0.12 , 70.56]
1.49 [0.21 , 10.76]
Risk Ratio
M-H, Fixed, 95% CI
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Analysis 1.11.   (Continued)
Total events:
Heterogeneity: Chi² = 0.35, df = 1 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Chi² = 0.13, df = 3 (P = 0.99), I² = 0%
2 1
0.01 0.1 1 10 100
Favours fortified Favours control
 
 
Analysis 1.12.   Comparison 1: Fortified breast milk versus unfortified breast milk, Outcome 12:
Serum ALP (IU/L): restricted to trials without mineral supplementation of the control group
Study or Subgroup
1.12.1 All trials
Einloft 2015
Gathwala 2012
Modanlou 1986
Mukhopadhyay 2007
Pettifor 1989
Zuckerman 1994
Subtotal (95% CI)
Heterogeneity: Chi² = 12.51, df = 5 (P = 0.03); I² = 60%
Test for overall effect: Z = 4.49 (P < 0.00001)
1.12.2 Trials recruiting only very preterm or VLBW infants
Modanlou 1986
Mukhopadhyay 2007
Pettifor 1989
Zuckerman 1994
Subtotal (95% CI)
Heterogeneity: Chi² = 8.98, df = 3 (P = 0.03); I² = 67%
Test for overall effect: Z = 3.92 (P < 0.0001)
1.12.3 Trials conducted in low- or middle-income countries
Gathwala 2012
Mukhopadhyay 2007
Pettifor 1989
Zuckerman 1994
Subtotal (95% CI)
Heterogeneity: Chi² = 8.62, df = 3 (P = 0.03); I² = 65%
Test for overall effect: Z = 3.56 (P = 0.0004)
1.12.4 Trials using preterm formula powder as fortifier
Zuckerman 1994
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.84 (P = 0.07)
Test for subgroup differences: Chi² = 1.05, df = 3 (P = 0.79), I² = 0%
Fortified
Mean
391
711
790
556
483
620
790
556
483
620
711
556
483
620
620
SD
177
646
202
231
152
368
202
231
152
368
646
231
152
368
368
Total
19
30
7
82
29
18
185
7
82
29
18
136
30
82
29
18
159
18
18
Unfortified
Mean
720
719
1075
636
843
881
1075
636
843
881
719
636
843
881
881
SD
465
542
434
245
514
435
434
245
514
435
542
245
514
435
435
Total
19
30
9
75
30
15
178
9
75
30
15
129
30
75
30
15
150
15
15
Weight
7.7%
4.2%
3.7%
69.0%
10.4%
5.0%
100.0%
4.2%
78.3%
11.8%
5.6%
100.0%
4.8%
77.9%
11.8%
5.6%
100.0%
100.0%
100.0%
Mean Difference
IV, Fixed, 95% CI
-329.00 [-552.72 , -105.28]
-8.00 [-309.75 , 293.75]
-285.00 [-605.61 , 35.61]
-80.00 [-154.66 , -5.34]
-360.00 [-552.07 , -167.93]
-261.00 [-539.14 , 17.14]
-141.93 [-203.93 , -79.92]
-285.00 [-605.61 , 35.61]
-80.00 [-154.66 , -5.34]
-360.00 [-552.07 , -167.93]
-261.00 [-539.14 , 17.14]
-132.03 [-198.09 , -65.98]
-8.00 [-309.75 , 293.75]
-80.00 [-154.66 , -5.34]
-360.00 [-552.07 , -167.93]
-261.00 [-539.14 , 17.14]
-119.66 [-185.54 , -53.78]
-261.00 [-539.14 , 17.14]
-261.00 [-539.14 , 17.14]
Mean Difference
IV, Fixed, 95% CI
-500 -250 0 250 500
Favours fortified Favours control
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Analysis 1.13.   Comparison 1: Fortified breast milk versus unfortified breast milk, Outcome 13: Bone
mineral content (mg/cm): restricted to trials without mineral supplementation of the control group
Study or Subgroup
Pettifor 1989
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 4.11 (P < 0.0001)
Test for subgroup differences: Not applicable
Treatment
Mean
59
SD
13
Total
29
29
Control
Mean
47
SD
9
Total
30
30
Weight
100.0%
100.0%
Mean Difference
IV, Fixed, 95% CI
12.00 [6.28 , 17.72]
12.00 [6.28 , 17.72]
Mean Difference
IV, Fixed, 95% CI
-10 -5 0 5 10
Favours control Favours fortified
 
 
A P P E N D I C E S
Appendix 1. Search strategy
Cochrane Central Register of Controlled Trials (CENTRAL)
Wiley http://onlinelibrary.wiley.com/
Issue 9 of 12, September 2019
Searched on: 26th September 2019
Records retrieved: 714
#1 MeSH descriptor: [Infant, Newborn] explode all trees 15243
#2 MeSH descriptor: [Premature Birth] this term only 1155
#3 (neonat* or neo next nat*):ti,ab,kw 20707
#4 (newborn* or new next born* or newly next born*):ti,ab,kw 26166
#5 (preterm or preterms or pre next term or pre next terms):ti,ab,kw 12761
#6 (preemie* or premie or premies):ti,ab,kw 44
#7 (prematur* near/3 (birth* or born or deliver*)):ti,ab,kw 2481
#8 (low near/3 (birthweight* or birth next weight*)):ti,ab,kw 5297
#9 (lbw or vlbw or elbw):ti,ab,kw 1576
#10 infan*:ti,ab,kw 58312
#11 (baby or babies):ti,ab,kw 7655
#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 73825
#13 MeSH descriptor: [Milk, Human] this term only 959
#14 MeSH descriptor: [Milk Banks] this term only 5
#15 MeSH descriptor: [Breast Milk Expression] this term only 24
#16 #13 or #14 or #15 972
#17 MeSH descriptor: [Food, Fortified] this term only 1362
#18 MeSH descriptor: [Dietary Supplements] this term only 9483
#19 #17 or #18 10677
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#20 #16 and #19 273
#21 (fortif* near/4 ((human* or breast or express*) near/2 milk*)):ti,ab,kw 271
#22 (fortif* near/4 ((mother* or maternal or donor* or donat* or bank*) near/2 milk*)):ti,ab,kw 55
#23 (supplement* near/4 ((human* or breast or express*) near/2 milk*)):ti,ab,kw 279
#24 (supplement* near/4 ((mother* or maternal or donor* or donat* or bank*) near/2 milk*)):ti,ab,kw 70
#25 (enrich* near/4 ((human* or breast or express*) near/2 milk*)):ti,ab,kw 37
#26 (enrich* near/4 ((mother* or maternal or donor* or donat* or bank*) near/2 milk*)):ti,ab,kw 7
#27 ((fortif* or supplement* or enrich*) near/4 DHM):ti,ab,kw 3
#28 ((fortif* or supplement* or enrich*) near/4 HM):ti,ab,kw 39
#29 ((fortif* or supplement* or enrich*) near/4 breastmilk*):ti,ab,kw 30
#30 ((fortif* or supplement* or enrich*) near/3 (multinutrient* or multi next nutrient* or multicomponent* or multi next
component*)):ti,ab,kw 106
#31 ((supplement* or enrich*) near/3 (bovine* or cow* or donkey*) near/3 milk*):ti,ab,kw 54
#32 (fortif* near/5 (bovine* or cow* or donkey*)):ti,ab,kw 64
#33 #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 758
#34 #20 or #33 904
#35 #12 and #34 734
#36 #12 and #34 in Trials 714
MEDLINE ALL
(includes: Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE)
OvidSP http://ovidsp.ovid.com/
1946 to September 24, 2019
Searched on: 26th September 2019
Records retrieved: 735
1 exp Infant, Newborn/ (590174)
2 Premature Birth/ (12627)
3 (neonat$ or neo nat$).ti,ab. (252905)
4 (newborn$ or new born$ or newly born$).ti,ab. (160734)
5 (preterm or preterms or pre term or pre terms).ti,ab. (70462)
6 (preemie$ or premie or premies).ti,ab. (164)
7 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (15050)
8 (low adj3 (birthweight$ or birth weight$)).ti,ab. (33172)
9 (lbw or vlbw or elbw).ti,ab. (7969)
10 infan$.ti,ab. (420915)
11 (baby or babies).ti,ab. (67489)
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12 or/1-11 (1021962)
13 Milk, Human/ (18549)
14 Milk Banks/ (461)
15 Breast Milk Expression/ (271)
16 13 or 14 or 15 (18750)
17 Food, Fortified/ (9079)
18 Dietary Supplements/ (53248)
19 17 or 18 (61296)
20 16 and 19 (894)
21 (fortif$ adj4 ((human$ or breast or express$) adj2 milk$)).ti,ab. (549)
22 (fortif$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).ti,ab. (96)
23 (supplement$ adj4 ((human$ or breast or express$) adj2 milk$)).ti,ab. (460)
24 (supplement$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).ti,ab. (107)
25 (enrich$ adj4 ((human$ or breast or express$) adj2 milk$)).ti,ab. (90)
26 (enrich$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).ti,ab. (15)
27 ((fortif$ or supplement$ or enrich$) adj4 DHM).ti,ab. (18)
28 ((fortif$ or supplement$ or enrich$) adj4 HM).ti,ab. (114)
29 ((fortif$ or supplement$ or enrich$) adj4 breastmilk$).ti,ab. (47)
30 ((fortif$ or supplement$ or enrich$) adj3 (multinutrient$ or multi-nutrient$ or multicomponent$ or multi-component$)).ti,ab. (152)
31 ((supplement$ or enrich$) adj3 (bovine$ or cow$ or donkey$) adj3 milk$).ti,ab. (228)
32 (fortif$ adj5 (bovine$ or cow$ or donkey$)).ti,ab. (229)
33 or/21-32 (1727)
34 20 or 33 (2236)
35 12 and 34 (1663)
36 randomised controlled trial.pt. (489981)
37 controlled clinical trial.pt. (93266)
38 randomized.ab. (454848)
39 placebo.ab. (200736)
40 drug therapy.fs. (2141859)
41 randomly.ab. (318352)
42 trial.ab. (476880)
43 groups.ab. (1955276)
44 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 (4527911)
45 exp animals/ not humans.sh. (4618767)
46 44 not 45 (3919813)
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47 35 and 46 (735)
Embase
OvidSP http://ovidsp.ovid.com/
1974 to 2019 September 25
Searched on: 26th September 2019
Records retrieved: 978
1 newborn/ (510070)
2 prematurity/ (97287)
3 exp low birth weight/ (59374)
4 (neonat$ or neo nat$).ti,ab. (328678)
5 (newborn$ or new born$ or newly born$).ti,ab. (186945)
6 (preterm or preterms or pre term or pre terms).ti,ab. (99681)
7 (preemie$ or premie or premies).ti,ab. (249)
8 (prematur$ adj3 (birth$ or born or deliver$)).ti,ab. (20715)
9 (low adj3 (birthweight$ or birth weight$)).ti,ab. (41955)
10 (lbw or vlbw or elbw).ti,ab. (10924)
11 infan$.ti,ab. (480027)
12 (baby or babies).ti,ab. (93471)
13 or/1-12 (1102074)
14 breast milk/ (26236)
15 milk banks/ (172)
16 donor milk/ (96)
17 breast milk expression/ (319)
18 or/14-17 (26483)
19 fortified food/ (923)
20 diet supplementation/ (83893)
21 dietary supplement/ (10128)
22 exp nutrition supplement/ (14952)
23 mineral supplementation/ (1534)
24 vitamin supplementation/ (31158)
25 or/19-24 (137963)
26 18 and 25 (1662)
27 (fortif$ adj4 ((human$ or breast or express$) adj2 milk$)).ti,ab. (767)
28 (fortif$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).ti,ab. (131)
29 (supplement$ adj4 ((human$ or breast or express$) adj2 milk$)).ti,ab. (559)
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30 (supplement$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).ti,ab. (130)
31 (enrich$ adj4 ((human$ or breast or express$) adj2 milk$)).ti,ab. (118)
32 (enrich$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).ti,ab. (17)
33 ((fortif$ or supplement$ or enrich$) adj4 DHM).ti,ab. (23)
34 ((fortif$ or supplement$ or enrich$) adj4 HM).ti,ab. (164)
35 ((fortif$ or supplement$ or enrich$) adj4 breastmilk$).ti,ab. (59)
36 ((fortif$ or supplement$ or enrich$) adj3 (multinutrient$ or multi-nutrient$ or multicomponent$ or multi-component$)).ti,ab. (203)
37 ((supplement$ or enrich$) adj3 (bovine$ or cow$ or donkey$) adj3 milk$).ti,ab. (274)
38 (fortif$ adj5 (bovine$ or cow$ or donkey$)).ti,ab. (306)
39 or/27-38 (2244)
40 26 or 39 (3544)
41 13 and 40 (2587)
42 randomised controlled trial/ (573423)
43 controlled clinical trial/ (465486)
44 42 or 43 (759228)
45 Random$.ti,ab. (1463071)
46 randomizations/ (84472)
47 intermethod comparison/ (254409)
48 placebo.ti,ab. (296225)
49 (compare or compared or comparison).ti. (492537)
50 ((evaluated or evaluate or evaluating or assessed or assess) and (compare or compared or comparing or comparison)).ab. (1997679)
51 (open adj label).ti,ab. (74701)
52 ((double or single or doubly or singly) adj (blind or blinded or blindly)).ti,ab. (224895)
53 double blind procedure/ (166551)
54 parallel group$1.ti,ab. (24383)
55 (crossover or cross over).ti,ab. (100855)
56 ((assign$ or match or matched or allocation) adj5 (alternate or group$1 or intervention$1 or patient$1 or subject$1 or participant
$1)).ti,ab. (315479)
57 (assigned or allocated).ti,ab. (370048)
58 (controlled adj7 (study or design or trial)).ti,ab. (331556)
59 (volunteer or volunteers).ti,ab. (239725)
60 human experiment/ (469138)
61 trial.ti. (282787)
62 or/44-61 (4781482)
63 41 and 62 (978)
Multi-nutrient fortification of human milk for preterm infants (Review)
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
56
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
CINAHL Complete
via EBSCO http://www.ebsco.com/
Inception to 25th September 2019
Searched on: 26th September 2019
Records retrieved: 33
 
S57 S31 AND S56 371
S56 S47 OR S55 1,085,472
S55 S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 824,161
S54 TI before N3 after OR AB before N3 after 66,639
S53 (MH "Controlled Before-After Studies") 128
S52 TI ( multicentre* or multi-centre* or multicenter* or multi-center* ) OR AB ( multi-
centre* or multi-centre* or multicenter* or multi-center* )
44,660
S51 (MH "Multicenter Studies") 140,466
S50 TI assign* OR AB assign* 66,850
S49 TI ( group or groups ) OR AB ( group or groups ) 644,433
S48 (MH "Control Group") 11,172
S47 S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46
622,565
S46 AB (cluster W3 RCT) 301
S45 MH (crossover design) OR MH (comparative studies) 233,540
S44 AB (control W5 group) 94,252
S43 PT (randomised controlled trial) 86,755
S42 MH (placebos) 11,452
S41 MH (sample size) AND AB (assigned OR allocated OR control) 3,698
S40 TI trial 95,074
S39 AB random* 268,743
S38 TI randomised OR randomised 93,017
S37 (MH "Cluster Sample") 3,883
S36 (MH "Pretest-Posttest Design") 39,135
S35 (MH "Random Assignment") 56,283
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S34 (MH "Single-Blind Studies") 12,796
S33 (MH "Double-Blind Studies") 42,482
S32 (MH "Randomized Controlled Trials") 86,398
S31 S13 AND S30 787
S30 S16 OR S29 989
S29 S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28
589
S28 TI ( (supplement* or enrich*) N3 (bovine* or cow* or donkey*) N3 milk*) ) OR AB
( (supplement* or enrich*) N3 (bovine* or cow* or donkey*) N3 milk*) )
40
S27 TI ( (fortif* or supplement* or enrich*) N3 (multinutrient* or multi-nutrient* or mul-
ticomponent* or multi-component*) ) OR AB ( (fortif* or supplement* or enrich*) N3
(multinutrient* or multi-nutrient* or multicomponent* or multi-component*) )
71
S26 TI ( (fortif* N5 (bovine* or cow* or donkey*)) ) OR AB ( (fortif* N5 (bovine* or cow* or
donkey*)) )
47
S25 TI ( ((fortif* or supplement* or enrich*) N4 breastmilk*) ) OR AB ( ((fortif* or supple-
ment* or enrich*) N4 breastmilk*) )
14
S24 TI ( ((fortif* or supplement* or enrich*) N4 HM) ) OR AB ( ((fortif* or supplement* or
enrich*) N4 HM) )
26
S23 TI ( ((fortif* or supplement* or enrich*) N4 DHM) ) OR AB ( ((fortif* or supplement* or
enrich*) N4 DHM) )
8
S22 TI ( (enrich* N4 ((mother* or maternal or donor* or donat* or bank*) N2 milk*)) ) OR
AB ( (enrich* N4 ((mother* or maternal or donor* or donat* or bank*) N2 milk*)) )
5
S21 TI ( (enrich* N4 ((human* or breast or express*) N2 milk*)) ) OR AB ( (enrich* N4 ((hu-
man* or breast or express*) N2 milk*)) )
23
S20 TI ( (supplement* N4 ((mother* or maternal or donor* or donat* or bank*) N2
milk*)) ) OR AB ( (supplement* N4 ((mother* or maternal or donor* or donat* or
bank*) N2 milk*)) )
49
S19 TI ( (supplement* N4 ((human* or breast or express*) N2 milk*)) ) OR AB ( (supple-
ment* N4 ((human* or breast or express*) N2 milk*)) )
169
S18 TI ( (fortif* N4 ((mother* or maternal or donor* or donat* or bank*) N2 milk*)) ) OR
AB ( (fortif* N4 ((mother* or maternal or donor* or donat* or bank*) N2 milk*)) )
35
S17 TI ( (fortif* N4 ((human* or breast or express*) N2 milk*)) ) OR AB ( (fortif* N4 ((hu-
man* or breast or express*) N2 milk*)) )
255
S16 S14 AND S15 582
S15 (MH "Food, Fortified") or (MH "Dietary Supplements") or (MH "Dietary Supplemen-
tation") or (MH "Infant Feeding, Supplemental")
39,564
S14 (MH "Milk, Human+") or (MH "Milk Expression") or (MH "Milk Banks") 5,692
  (Continued)
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S13 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 OR S12 223,811
S12 TI ( baby or babies ) OR AB ( baby or babies ) 27,781
S11 TI infan* OR AB infan* 96,039
S10 TI ( lbw or vlbw or elbw ) OR AB ( lbw or vlbw or elbw ) 2,827
S9 TI ( low N3 (birthweight* or birth-weight*) ) OR AB ( low N3 (birthweight* or birth-
weight*) )
10,367
S8 TI ( prematur* N3 (birth* or born or deliver*) ) OR AB ( prematur* N3 (birth* or born
or deliver*) )
3,897
S7 TI ( preemie* or premie or premies ) OR AB ( preemie* or premie or premies ) 280
S6 TI ( preterm or preterms or pre-term or pre-terms ) OR AB ( preterm or preterms or
pre-term or pre-terms)
27,710
S5 TI ( newborn* or new-born* or newly N1 born* ) OR AB ( newborn* or new-born* or
newly N1 born* )
26,361
S4 TI ( neonat* or neo-nat* ) OR AB ( neonat* or neo-nat* ) 56,313
S3 MH "Infant, Premature" 20,206
S2 MH "Infant, Low Birth Weight+" 12,383
S1 MH "Infant, Newborn+" 122,798
  (Continued)
 
Maternity and Infant Care
OvidSP http://ovidsp.ovid.com/
1971 to August 2019
Searched on: 26th September 2019
Records retrieved: 371
1 (fortif$ adj4 ((human$ or breast or express$) adj2 milk$)).mp. (251)
2 (fortif$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).mp. (39)
3 (supplement$ adj4 ((human$ or breast or express$) adj2 milk$)).mp. (165)
4 (supplement$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).mp. (44)
5 (enrich$ adj4 ((human$ or breast or express$) adj2 milk$)).mp. (14)
6 (enrich$ adj4 ((mother$ or maternal or donor$ or donat$ or bank$) adj2 milk$)).mp. (4)
7 ((fortif$ or supplement$ or enrich$) adj4 DHM).mp. (5)
8 ((fortif$ or supplement$ or enrich$) adj4 HM).mp. (22)
9 ((fortif$ or supplement$ or enrich$) adj4 breastmilk$).mp. (21)
10 ((fortif$ or supplement$ or enrich$) adj3 (multinutrient$ or multi-nutrient$ or multicomponent$ or multi-component$)).mp. (24)
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11 ((supplement$ or enrich$) adj3 (bovine$ or cow$ or donkey$) adj3 milk$).mp. (12)
12 (fortif$ adj5 (bovine$ or cow$ or donkey$)).mp. (31)
13 or/1-12 (484)
Search filters to limit retrieval to randomised controlled trials were applied in MEDLINE (Lefebvre 2011), Embase (https://
www.cochranelibrary.com/central/central-creation) and CINAHL (Glanville 2019).
---------------------------------------------------------------------------------------------------------------------------------------------------------------------
ClinicalTrials.gov
https://clinicaltrials.gov/
Searched on: 30th September 2019
Records retrieved: 237
The following search strings were entered into the advanced search screen:
1. 59 Studies found for: (milk OR breastmilk) AND (fortify OR fortifying OR fortified OR fortifies OR fortifier) | Preterm OR pre-term OR
premature OR prematurity OR preemie OR premie OR low birth weight OR low birthweight OR LBW OR VLBW OR ELBW OR neonate OR
newborn
2. 161 Studies found for: (milk OR breastmilk) AND (supplement OR supplements OR supplemented OR supplementing OR
supplementation) | Preterm OR pre-term OR premature OR prematurity OR preemie OR premie OR low birth weight OR low birthweight
OR LBW OR VLBW OR ELBW OR neonate OR newborn
3. 13 Studies found for: (milk OR breastmilk) AND (enrich OR enriched OR enrichment OR enriching) | Preterm OR pre-term OR premature
OR prematurity OR preemie OR premie OR low birth weight OR low birthweight OR LBW OR VLBW OR ELBW OR neonate OR newborn
4. 4 Studies found for: (multinutrient OR multi-nutrient OR multicomponent OR multi-component) AND (milk OR breastmilk) | Preterm OR
pre-term OR premature OR prematurity OR preemie OR premie OR low birth weight OR low birthweight OR LBW OR VLBW OR ELBW OR
neonate OR newborn
WHO International Clinical Trials Registry Platform (ICTRP)
http://apps.who.int/trialsearch/
Searched on: 30th September 2019
Records retrieved: 101
The following search strings were entered into the advanced search screen:
1. 37 records for 36 trials
CONDITION: Preterm OR pre-term OR premature OR prematurity OR preemie OR premie OR low birth weight OR low birthweight OR LBW
OR VLBW OR ELBW OR neonate OR neo-nate OR neonatal OR neo-natal OR newborn
INTERVENTION: fortif AND milk
2. 54 records for 54 trials
CONDITION: Preterm OR pre-term OR premature OR prematurity OR preemie OR premie OR low birth weight OR low birthweight OR LBW
OR VLBW OR ELBW OR neonate OR neo-nate OR neonatal OR neo-natal OR newborn
INTERVENTION: supplement AND milk
3. 9 records for 9 trials
CONDITION: Preterm OR pre-term OR premature OR prematurity OR preemie OR premie OR low birth weight OR low birthweight OR LBW
OR VLBW OR ELBW OR neonate OR neo-nate OR neonatal OR neo-natal OR newborn
INTERVENTION: enrich AND milk
4. 2 records for 2 trials
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CONDITION: Preterm OR pre-term OR premature OR prematurity OR preemie OR premie OR low birth weight OR low birthweight OR LBW
OR VLBW OR ELBW OR neonate OR neo-nate OR neonatal
INTERVENTION: multinutrient OR multi-nutrient OR multicomponent
Appendix 2. Risk of bias
1. Sequence generation (checking for possible selection bias). Was the allocation sequence adequately generated?
For each included study, we categorised the method used to generate the allocation sequence as:
• low risk (any truly random process e.g. random number table; computer random number generator);
• high risk (any non-random process e.g. odd or even date of birth; hospital or clinic record number); or
• unclear risk.
2. Allocation concealment (checking for possible selection bias). Was allocation adequately concealed?
For each included study, we categorised the method used to conceal the allocation sequence as:
• low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);
• high risk (open random allocation; unsealed or non-opaque envelopes, alternation; date of birth); or
• unclear risk.
3. Blinding of participants and personnel (checking for possible performance bias). Was knowledge of the allocated intervention
adequately prevented during the study?
For each included study, we categorised the methods used to blind study participants and personnel from knowledge of which intervention
a participant received. Blinding was assessed separately for diHerent outcomes or class of outcomes. We categorised the methods as:
• low risk, high risk, or unclear risk for participants; and
• low risk, high risk, or unclear risk for personnel.
4. Blinding of outcome assessment (checking for possible detection bias). Was knowledge of the allocated intervention adequately
prevented at the time of outcome assessment?
For each included study, we categorised the methods used to blind outcome assessment. Blinding was assessed separately for diHerent
outcomes or classes of outcomes. We categorised the methods as:
• low risk for outcome assessors;
• high risk for outcome assessors; or
• unclear risk for outcome assessors.
5. Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations). Were incomplete
outcome data adequately addressed?
For each included study and for each outcome, we described the completeness of data including attrition and exclusions from the analysis.
We noted whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total
randomised participants), reasons for attrition or exclusion when reported, and whether missing data were balanced across groups or
were related to outcomes. When suHicient information was reported or supplied by the trial authors, we re-included missing data in the
analyses. We categorised the methods as:
• low risk (< 20% missing data);
• high risk (≥ 20% missing data); or
• unclear risk.
6. Selective reporting bias. Are reports of the study free of the suggestion of selective outcome reporting?
For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. For
studies in which study protocols were published in advance, we compared pre-specified outcomes versus outcomes eventually reported in
the published results. If the study protocol was not published in advance, we contacted study authors to gain access to the study protocol.
We assessed the methods as:
• low risk (when it is clear that all of the study's pre-specified outcomes and all expected outcomes of interest to the review have been
reported);
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• high risk (when not all of the study's pre-specified outcomes have been reported; one or more reported primary outcomes were not
pre-specified outcomes of interest and are reported incompletely and so cannot be used; study fails to include results of a key outcome
that would have been expected to have been reported); or
• unclear risk.
7. Other sources of bias. Was the study apparently free of other problems that could put it at high risk of bias?
For each included study, we described any important concerns we had about other possible sources of bias (e.g. whether there was a
potential source of bias related to the specific study design, whether the trial was stopped early due to some data-dependent process). We
assessed whether each study was free of other problems that could put it at risk of bias as:
• low risk;
• high risk; or
• unclear risk.
If needed, we explored the impact of the level of bias through undertaking sensitivity analyses.
Appendix 3. GRADE
GRADE considers that evidence from randomised controlled trials is of high certainty, but that assessment may be downgraded based on
consideration of any of five areas.
• Design (risk of bias).
• Consistency across studies.
• Directness of evidence.
• Precision of estimates.
• Presence of publication bias.
This results in an assessment of the certainty of a body of evidence in one of four grades.
High certainty: we are very confident that the true eHect lies close to that of the estimate of the eHect.
Moderate certainty: we are moderately confident in the eHect estimate; the true eHect is likely to be close to the estimate of the eHect,
but there is a possibility that it is substantially diHerent.
Low certainty: our confidence in the eHect estimate is limited; the true eHect may be substantially diHerent from the estimate of the eHect.
Very low certainty: we have very little confidence in the eHect estimate; the true eHect is likely to be substantially diHerent from the
estimate of eHect.
W H A T ' S   N E W
 
Date Event Description
7 July 2020 Amended Information regarding The Gerber Foundation added to Declara-
tions of interest section
 
H I S T O R Y
Protocol first published: Issue 4, 1998
Review first published: Issue 4, 1998
 
Date Event Description
24 April 2020 New citation required but conclusions
have not changed
The updated review includes 4 new studies, but the conclusions
remain unchanged.
24 April 2020 New search has been performed This review updates "Multicomponent fortified human milk for
promoting growth in preterm infants," published in the Cochrane
Library, Issue 11, 2003.
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Date Event Description
29 August 2003 New search has been performed This review updates the existing review titled, "Multicomponent
fortified human milk for promoting growth in preterm infants",
published in the Cochrane Library, Issue 4, 1998
This review presents 6 new studies (included - Zuckerman,
Nicholl, Faerk; excluded - Gupta, Porcelli, Reiss) and 1 follow-up
report (Wauben)
 
C O N T R I B U T I O N S   O F   A U T H O R S
Jennifer Brown, Luling Lin, and William McGuire screened and appraised reports identified in the updated search, extracted and
analysed data from included studies, and draTed the review. Nick Embleton and Jane Harding arbitrated inclusion and data extraction
disagreements and draTed the review.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We defined a "multi-nutrient" fortifier as one that contains both protein and non-protein energy (carbohydrate or fat) with the option of
including other nutrients, such as minerals, vitamins, or electrolytes.
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I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Food, Fortified;  *Infant Nutritional Physiological Phenomena;  Infant, Premature  [*growth & development];  Milk, Human  [*chemistry];
  Randomized Controlled Trials as Topic
MeSH check words
Humans; Infant, Newborn
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